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1. INTRODUCTION 
 
            An ideal dosage regimen in the drug therapy of any disease is the one which 
immediately attains the desired therapeutic concentration of drug in plasma (or at the site of 
action) and maintains it constant for entire duration of treatment. This is possible through 
administration of conventional dosage form in a particular dose at a particular frequency. 
Thus drug may administered by variety routes in variety of dosage form1. 
            Oral route is most common and popular route of administration of drug is oral route 
because of its systemic effect, patient compliance, less expensive to manufacture. Tablet 
provides high precision dosing. Tablet form is the most widely used dosage form because of 
self-administration and ease in manufacturing. In most of the cases immediate on set of 
action is required as compare to conventional therapy. To achieve the rapid onset of action 
and eliminate the drawbacks of conventional therapy immediate release dosage form is now a 
days popular and used as an alternative oral dosage form. Immediate release tablet are very 
quickly after administration. Basic approach used in development is the use of 
superdisintegrants which provide rapid disintegration of tablet after administration2. 
  
1.1. Types of Tablets [3, 4, 5]: 
       1. Tablets ingested orally 
a. Standard Compressed tablet 
b. Multiple compressed tablet 
i. Layered Tablet 
ii. Compression coated Tablet 
c. Repeat action Tablet 
d. Delayed action and enteric coated Tablet 
e. Sugar and chocolate coated tablet 
f. Film coated tablet 
g. Chewable Tablet 
h. Targeted tablet 
i. Floating tablet 
ii. Colon targeted tablet 
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These tablets are meant to be swallowed intact along with a sufficient quantity of 
potable water. Exception is chewable tablet. Over 90% of the tablets manufactured today are 
ingested orally. This shows that this class of formulation is the most popular worldwide and 
the major attention of the researcher is towards this direction. 
           2. Tablets used in the oral cavity: 
a. Buccal Tablet 
b. Sublingual Tablet 
c. Troches and Lozenges 
d. Dental cones 
e. Mouth dissolved tablet 
            The tablets under this group are aimed release API in oral cavity or to provide local 
action in this region. The tablets under this category avoids first-pass metabolism, 
decomposition in gastric environment, nauseatic sensations and gives rapid onset of action. 
The tablets formulated for this region are designed to fit in proper region of oral cavity. 
            3. Tablets administered by other routes: 
a. Implantation Tablet 
b. Vaginal Tablets 
            These tablets are administered by other route except for the oral cavity and so the 
drugs are avoided from passing through gastro intestinal tract. These tablets may be inserted 
into other body cavities or directly placed below the skin to be absorbed into systemic 
circulation from the site of application. 
            4. Tablets used to prepare solution: 
a. Effervescent Tablet 
b. Dispensing Tablet 
c. Hypodermic Tablet 
d. Tablets Triturates 
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1.2. Immediate Release Dosage Form 
  
            Immediate release tablets are designed to disintegrate and release the drug in absence 
of any controlling features such as coating or other formulation techniques6. The solution 
containing the active ingredients is swallowed, and the active ingredients are then absorbed 
through the gastrointestinal epithelium to reach the target and produce the desired effect7. 
              
1.3. Advantages of Tablets 
 
 They are unit dosage form, and they offer the capabilities of all oral dosage forms for 
the dose precision and the least content variability during dosing. 
 Accuracy and uniformity of drug content. 
 Optimal drug dissolution and hence, availability from the dosage form for absorption 
consistent with intended use (i.e., immediate or extended release). 
 Usually taken orally, but can be administered sublingually, rectally or intra-vaginally. 
 Their cost is lowest of all oral dosage form. 
 They are the most compact of all oral dosage forms. 
 They are in general the easier and cheaper to package and ship as compare to other 
oral dosage forms. 
 Product identification is simple and cheap, requiring no additional processing steps 
when employing an embossed or monogrammed punch face. 
 They are ease to administer, does not require a specialist. 
 They are better suited to large-scale production than other unit oral forms. 
 They have the better properties of chemical, mechanical and microbiological stability. 
 Easy to prepare. 
 Provide prolonged stability to medicaments. 
 Formulate as a special release products such as enteric or delayed release products. 
 Easy to divide into halves and quarters whenever fraction dose is required. 
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1.4. Problems With Existing Oral Dosage Form [11,12]: 
 
 Patient may suffer from tremors therefore they have difficulty to take powder and 
liquids. In dysphasia physical obstacles and adherence to an esophagus may cause 
gastrointestinal ulceration. 
 
 Swallowing of solid dosage forms like tablet and capsules and produce difficulty for 
young adult of incomplete development of muscular and nervous system and elderly 
patients suffer from dysphasia. 
 
 Liquid medicaments (suspension and emulsion) are packed in multidose container; 
therefore achievement of uniformity in the content of each dose may be difficult. 
 
 Buccal and sublingual formation may cause irritation to oral mucosa, so patients 
refused to use such medications. 
 
 Cost of products is main factor as parenteral formulations are most costly and 
discomfort. 
 
1.5. Desired Criteria For Immediate Release Drug Delivery System [13,14]:  
 
 In the case of solid dosage it should dissolve or disintegrate in the stomach within a 
short period. 
 
 In the case of liquid dosage form it should be compatible with taste masking. 
 
 Be portable without fragility concern. 
 
 Have a pleasing mouth feel. 
 
 It should not leave minimal or no residue in the mouth after oral administration. 
 
 Exhibit low sensitivity to environmental condition as humidity and temperature. 
 
 Be manufactured using conventional processing and packaging equipment at low cost. 
  
 Rapid dissolution and absorption of drug, which may produce rapid onset of action. 
 
 
 
 
                                                                                   INTRODUCTION 
 
Department of pharmaceutics Page 5 
 
1.6. Merits of Immediate Release Drug Delivery System [15]: 
 
 Improved compliance/added convenience 
 
 Improved stability, bioavailability 
 
 Suitable for controlled/sustained release actives 
 
 Allows high drug loading 
 
 Ability to provide advantages of liquid medication in the form of solid preparation. 
 
 Adaptable and amenable to existing processing and packaging machinery 
 
 Cost- effective 
 
 Improved solubility of the pharmaceutical composition 
 
 Decreased disintegration and dissolution times for immediate release oral dosage 
forms. 
 
Bulking Agents 
 
            Bulking agents are significant in the formulation of fast-melting tablets. The material 
contributes functions of a diluents, filler and cost reducer. Bulking agents improve the 
textural characteristics that in turn enhance the disintegration in the mouth, besides; adding 
bulk also reduces the concentration of the active in the composition. The recommended 
bulking agents for this delivery system should be more sugar-based such as mannitol, 
polydextrose, lactitol, DCL (direct compressible lactose) and starch hydrolystate for higher 
aqueous solubility and good sensory perception. Mannitol in particular has high aqueous 
solubility and good sensory perception. Bulking agents are added in the range of 10 percent 
to about 90 percent by weight of the final composition. 
 
Lubricants 
 
            Lubricants, though not essential excipients, can further assist in making these tablets 
more palatable after they disintegrate in the mouth. Lubricants remove grittiness and assist in 
the drug transport mechanism from the mouth down into the stomach. 
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Carrier Materials 
 
            For therapeutic purposes, the pharmaceutical compositions of the present invention 
comprise micronized   drug in a desired   amount in combination with one or more 
pharmaceutically-acceptable carrier materials appropriate to the indicated route of 
administration. 
 
            Oral dosage forms of the pharmaceutical compositions of the present invention 
preferably comprise micronized drug in a desired amount admixed with one or more carrier 
materials selected from the group consisting of diluents, disintegrants, binding agents and 
adhesives, wetting agents, lubricants, anti-adherent agents and/or other carrier materials. 
More preferably, such compositions are tableted or encapsulated for convenient 
administration. Such capsules or tablets can be in the form of immediate release capsules or 
tablets, or can contain a controlled-release formulation as can be provided. 
 
            For example, in a dispersion of drug in hydroxypropyl methylcellulose. Injectable 
dosage forms preferably are adapted for parenteral injection. Preferably, these dosage forms 
comprise micronized drug in aqueous or non-aqueous isotonic sterile injection solutions or 
suspensions, such as drug suspended or dissolved in water, polyethylene glycol, propylene 
glycol, ethanol, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium 
chloride, and/or various buffers. These solutions and suspensions can be prepared from sterile 
powders or granules having one or more of the carriers or diluents mentioned for use in the 
formulations for oral administration. 
          
Super Disintegrants33 
 
            A disintegrant is an excipient, which is added to a tablet or capsule blend to aid in the 
breakup of the compacted mass when it is put into a fluid environment.  
     
            Pharmaceutical products designed for oral delivery and currently available on the 
prescription and over-the-counter markets are mostly the immediate release type, which are 
designed for immediate release of drug for rapid absorption. Disintegrating agents are 
substances routinely included in tablet formulations and in some hard shell capsule 
formulations to promote moisture penetration and dispersion of the matrix of the dosage form 
in dissolution fluids.    
 
            Superdisintegrant improve disintegrant efficiency resulting in decreased use levels 
when compared to traditional disintegrants. Traditionally, starch has been the disintegrant of 
choice in tablet formulation, and it is still widely used. For instance, starch generally has to 
be present at levels greater than 5% to adversely affect compatibility, especially in direct 
compression. Drug release from a solid dosage form can be enhanced by addition of suitable 
disintegrants8. 
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Mechanism of Disintegrants9,10: 
 
1) High swellability 
2) Capillary action and high swellability 
3) Chemical reaction 
            When introduced to an aqueous environment of use, the tablet rapidly takes up water, 
leading to swelling of the disintegrant and rapid disintegration of the tablet before the 
dispersion polymer can form a hydrogel. The disintegrant should be chosen such that it:  
 
            (1) Swells rapidly when introduced into the use environment  
            (2) Has a low tendency to form or promote formation of a hydrogel.  
 
            The rate of swelling of the disintegrant is directly correlated to tablet disintegration 
times. Tablets containing disintegrants cause more rapid swelling have faster disintegration 
times at comparable disintegrant levels. The amount of work, W, or swelling energy, due to 
swelling can be measured using a dynamic mechanical analyzer (DMA). The swelling energy 
attributable to swelling of the disintegrant in the compact may be calculated from the 
following equation: 
 
 
 
 
 
                        Where,  
 
                                 W is the work or swelling energy of the disintegrant, 
                                  P is the pressure applied by the probe,  
                                  ΔV is the volume change of the sample. 
 
            To compare disintegrants, the swelling energy per mass of disintegrant is used. 
Preferably, the disintegrant generates a swelling energy of at least 0.05 J/g within about 10 
minutes following addition of water to the liquid reservoir. The most popular disintegrants are 
corn starch, soluble starch etc. which have been well dried and powdered. Starches have great 
affinity for water and swell when moistened thus facilitating the rupture of the tablet matrix, 
its disintegration action in tablets is due to capillary action. Spherical shape of starch 
increases the porosity of tablet thus promoting capillary action. 
             
 
W=PΔV 
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            Classification of “Superdisintegrant” may be organized into three classes based on 
their chemical structure. As shown in Table below. 
 
Table No.1.1: Classification of Super disintegerants 
 
Disintegerants 
 
Concentration in granules (%) 
 
Special comments 
Starch USP 5-20 Higher amount is required, 
poorly compressible 
Starch 1500 5-15 - 
 
Avicel®(PH 101,PH 102) 
 
10-20 
 
 Lubricant properties and 
directly compressible 
 
Solka floc 5-15 Purified wood cellulose 
Alginic acids 1-5 Acts by swelling 
Na alginate 2.5-10 Acts by swelling 
Explotab 
 
2-8 
Sodium Starch glycolate 
Superdisintegerant 
Polyplasdone(XL) 0.5-5 Cross-linked PVP 
Amberlite (IPR 88) 0.5-5 Ion exchange resin 
Methyl cellulose, Na 
CMC 
HPMC 
 
5-10 
- 
 
AC-Di-Sol 
 
1-3 
Direct compression 
 
2-4 
Wet granulation 
 
Advantages: 
 
1. Effective in lower concentrations 
2. Less effect on compressibility and flow ability 
3. More effective intragranularly some super disintegrants are: 
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A. Sodium Starch Glycolate used in   concentration of 2-8 % and optimum is 4%. 
Mechanism of Action:  Rapid and extensive swelling   with minimal gelling. 
Microcrystalline cellulose (Synonym: Avicel, celex) used in concentration of 2-15% of 
tablet weight. And Water wicking. 
 
B. Cross-linked Povidone (crospovidone) used in concentration of 2-5% of weight of tablet. 
Mechanism of   Action: Water wicking, swelling and possibly some deformation 
recovery. Rapidly disperses and swells in water, but does not gel even after prolonged 
exposure. Greatest rate of swelling compared to other disintegrants. Greater surface area 
to volume ratio than other disintegrants. 
 
C. Low-substituted hydroxyl propyl cellulose, which is insoluble in water. Rapidly swells in 
water. Grades LH-11 and LH-21 exhibit the greatest degree of swelling. Certain grades 
can also provide some binding properties while retaining disintegration capacity. 
Recommended concentration 1-5%. 
 
D. Cross linked carboxy methyl cellulose sodium (i.e. Ac-Di-sol) Croscarmellose Sodium 
Mechanism of Action: Wicking due to fibrous structure, swelling with minimal gelling. 
Effective Concentrations: 1-3% Direct Compression, 2-4% Wet Granulation 
Conventional. 
 
Surfactants: 
 
            One very useful class of excipients is surfactants, preferably present from 0 to 10 wt 
%. Suitable surfactants include fatty acid and alkyl sulfonates; commercial surfactants such 
as benzalkonium chloride, dioctyl sodium sulfosuccinate, polyoxyethylene sorbitan fatty acid 
esters, natural surfactants such as sodium taurocholic acid, lecithin, and other phospholipids 
and mono- and diglycerides; and mixtures thereof. Such materials can advantageously be 
employed to increase the rate of dissolution by, for example, facilitating wetting, or otherwise 
increase the rate of drug release from the dosage form. 
  
 pH Modifiers: 
 
            Inclusion of pH modifiers such as acids, bases, or buffers may also be beneficial in an 
amount of from 0 to 10 wt %. Acidic pH modifiers (e.g., acids such as citric acid or succinic 
acid) retard the dissolution of the pharmaceutical composition when the dispersion polymer is 
anionic. Alternatively, basic pH modifiers (e.g., sodium acetate or amines) enhance the rate 
of dissolution of the same types of pharmaceutical composition. 
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Porosigen34: 
 
            The dosage form also includes a porosigen. A "porosigen" is a material that, when 
present in the formulation containing the solid amorphous dispersion, leads to a high porosity 
and high strength following compression of the blend into a tablet. In addition, preferred 
porosigen are soluble in an acidic environment with aqueous solubility typically greater than 
1 mg/mL at a pH less than about 5. 
 
            Examples of porosigens include acacia, calcium carbonate, calcium sulfate, calcium 
sulfate dihydrate, compressible sugar, dibasic calcium phosphate, tribasic calcium phosphate, 
monobasic sodium phosphate, dibasic sodium phosphate, lactose, magnesium oxide, 
magnesium carbonate, silicon dioxide, magnesium aluminum silicate, maltodextrin, mannitol, 
methyl cellulose, microcrystalline cellulose, sorbitol, sucrose, xylitol and mixtures thereof. 
 
            Generally, the porosigen will comprise from 5 to 70 wt %. To ensure the tablet has 
sufficient porosity to allow adequate wicking of water into the tablet to cause rapid tablet 
disintegration and/or rapid release of drug, tablet porosity should be within 0.15-0.25. 
Accordingly, the disintegrant, porosigen should be selected so that the immediate release 
dosage form has high strength as well as the high porosity required to achieve rapid 
disintegration and/or release of drug. 
 
Other Excipients  
 
            Excipients balance the properties of the actives in immediate release dosage forms. 
This demands a thorough understanding of the chemistry of these excipients to prevent 
interaction with the actives. Determining the cost of these ingredients is another issue that 
needs to be addressed by formulators. The role of excipients is important in the formulation 
of fast-melting tablets. These inactive food grade ingredients, when incorporated in the 
formulation, impart the desired organoleptic properties and product efficacy. Excipients are 
general and can be used for a broad range of actives, except some actives that require 
masking agents17. 
  
1.7. Technique Used In the Preparation of Immediate Release Tablets18 
 
 Tablet molding technique 
 Granulation technique 
 Direct compression technique 
 Mass extrusion technique Tablet Molding 
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1.7.1. Tablet molding technique27 
 
          In this technology, water-soluble ingredients are used so that tablet disintegrate and 
dissolve rapidly. The powder blend is moistened with a hydro alcoholic solvent and is 
molded into tablet using compression pressure lower than used in conventional tablets 
compression. The solvent is then removed by air-drying. Molded tablets have a porous 
structure that enhances dissolution.  
 
            Two problems commonly encountered are mechanical strength and poor taste 
masking characteristics. Using binding agents such as sucrose, acacia or poly vinyl 
pyrrolidone can increase the mechanical strength of the tablet. To overcome poor taste 
masking characteristic Van Scoik incorporated drug containing discrete particles, which were 
formed by spray congealing a molten mixture of hydrogenated cottonseed oil, sodium 
bicarbonate, lecithin, polyethylene glycol and active ingredient into a lactose based tablet 
triturate form. 
 
1.7.2. Mass extrusion technique Tablet Molding28 
 
            This technology involves softening the active blend using the solvent mixture of 
water-soluble polyethylene glycol and methanol and subsequent expulsion of softened mass 
through the extruder or syringe to get a cylinder of the product into even segments using 
heated blade to form tablets. The dried cylinder can also be used to coat granules for bitter 
drugs and thereby achieve taste masking 
 
            Immediate release solid dosage forms prepared by solid dispersions. When 
formulating such solid amorphous dispersions into immediate release solid dosage forms for 
oral administration to a use environment such as the GI tract of an animal such as a human, it 
is often desirable to maximize the amount of dispersion present in the dosage form. This 
minimizes the size of the solid dosage form required to achieve the desired dose. 
 
            Depending on the drug dose, it is often desired that the solid amorphous dispersion 
comprise at least 30 wt. %, preferably at least wt. %, and more preferably at least 50 wt % or 
more of the solid dosage form. Such high drug loadings of dispersion in a solid dosage form 
minimize the dosage form's size, making it easier for the patient to swallow it and tending to 
improve patient compliance.  
 
            The immediate release dosage forms containing a solid dispersion that enhances the 
solubility of a “low-solubility drug,” meaning that the drug may be either “substantially 
water-insoluble,” which means that the drug has a minimum aqueous solubility at 
physiologically relevant pH (e.g., pH 1-8) of less than 0.01 mg/mL, “sparingly water-
soluble,” that is, has an aqueous solubility up to about 1 to 2 mg/mL, or even low to moderate 
aqueous solubility, having an aqueous-solubility from about 1 mg/mL to as high as about 20 
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to 40 mg/ml. The drug dispersions used in fabricating the high loading immediate release 
dosage forms of the present invention comprise solid dispersions of a drug and at least one 
concentration enhancing polymer.    
  
1.7.3. Direct Compression Method41,42,43: 
 
            In this method, tablets are compressed directly from the mixture of the drug and 
excipients without any preliminary treatment. The mixture to be compressed must have 
adequate flow properties and cohere under pressure thus making pretreatment as wet 
granulation unnecessary. Few drugs can be directly compressed into tablets of acceptable 
quality. A type of disintegrant and its proportion are of prime importance. The other factors 
to be considered are particle size distribution, contact angle, pore size distribution, tablet 
hardness and water absorption capacity. All these factors determine the disintegration. The 
disintegrant addition technology is cost effective and easy to implement at industrial level. 
 
Advantages 
 
 Direct compression is more efficient and economical process as compared to other 
processes, because it involves only dry blending and compaction of API and 
necessary excipients. 
 The most important advantage of direct compression is that it is an less 
economical process. Reduced processing time, reduced labor costs, fewer 
manufacturing step, and less number of equipments are required, less process 
validation, reduced consumption of power. Elimination of heat and moisture, thus 
increasing not only the stability but also the suitability of the process for 
thermolabile and moisture sensitive API. 
 Particle size uniformity. 
 Prime particle dissolution. 
 In case of directly compressed tablets after disintegration, each primary drug 
particle is liberated. While in the case of tablets prepared by compression of 
granules, small drug particles with a larger surface area adhere together into larger 
agglomerates; thus decreasing the surface area available for dissolution. 
 The chances of batch-to-batch variation are negligible, because the unit operations 
required for manufacturing processes is fewer. 
 Chemical stability problems for API and excipient would be avoided. 
 Provides stability against the effect of aging which affects the dissolution rates. 
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Disadvantages 
Excipients Related 
 
 Problems in the uniform distribution of low dose drugs. High dose drugs having 
high bulk volume, poor compressibility and poor flow ability are not suitable for 
direct compression for example, Aluminium Hydroxide, Magnesium Hydroxide. 
 The choice of excipients for direct compression is extremely critical. Direct 
compression diluents and binders must possess both good compressibility and 
good flow ability. 
 Many active ingredients are not compressible either in crystalline or amorphous 
forms. 
 Direct compression blends may lead to unblending because of difference in 
particle size or density of drug and excipients. Similarly the lack of moisture may 
give rise to static charges, which may lead to unblending. 
 Non-uniform distribution of color, especially in tablets of deep colors 
 
1.7.4. Granulation29 
 
            Granulation may be defined as a size enlargement process which converts small 
particles into physically stronger & larger agglomerates. The objective of granulation is to 
improve powder flow and handling, decrease dustiness, and prevent segregation of the 
constituents of the product. 
            Granulation method can be broadly classified into two types: 
 
              1. Wet granulation and 
              2. Dry granulation Ideal characteristics of granules 
 
            The ideal characteristics of granules include spherical shape, smaller particle size 
distribution with sufficient fines to fill void spaces between granules, adequate moisture 
(between 1-2%), good flow, good compressibility and sufficient hardness. The effectiveness 
of granulation depends on the following properties: 
 
 Particle size of the drug and excipients 
 Type of binder (strong or weak) 
 Volume of binder (less or more) 
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 Wet massing time (less or more) 
 Amount of shear applied 
 Drying rate (Hydrate formation and polymorphism) 
 
(i) Wet granulation 30 
 
            Wet granulation is a commonly used unit operation in the pharmaceutical industry. 
Wet granulation is often carried out utilizing a high-shear mixer. The high-shear granulation 
process is a rapid process which is susceptible for over wetting. Thus, the liquid amount 
added is critical and the optimal amount is affected by the properties of the raw materials. 
Power consumption of the impeller motor and the impeller torque have been applied to 
monitor the rheological properties of the wet mass during agglomeration and, thereby, have 
been used to determine the end-point of water addition. However, these methods are affected 
by the equipment variables. Hence, additional process monitoring techniques would be 
valuable. Important steps involved in wet granulation. 
 
 Mixing of drug(s) and excipients. 
 Preparation of binder solution. 
 Mixing of binder solution with powder mixture to form wet mass. 
 Coarse screening of wet mass using a suitable sieve (6-12  screens). 
 Drying of moist granules. 
 Screening of dry granules through a suitable sieve (14-20 screen). 
 Mixing of screened granules with disintegrant, glidant, and lubricant. Limitation 
of wet granulation. 
Advantages 
 
 Rapid process. 
 Ability to be operated continuously. 
 Suitable for heat sensitive product. 
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Disadvantages 
                                        
 The greatest disadvantage of wet granulation is its cost. It is an expensive process 
because of labor, time, equipment, energy and space requirements. 
 Loss of material during various stages of processing 
 Stability may be a major concern for moisture sensitive or thermo labile drugs. 
 An inherent limitation of wet granulation is that any incompatibility between 
Formulation components is aggravated. It is a unique granulation technique that 
directly converts liquids into dry powder in a single step. This method removes 
Moisture instantly and converts pumpable liquids into a dry powder. 
 
(ii) Dry granulation (30, 31) 
 
            In dry granulation process the powder mixture is compressed without the use of heat 
and solvent. The two basic procedures are to form a compact of material by compression and 
then to mill the compact to obtain granules. Two methods are used for dry granulation. The 
more widely used method is slugging, where the powder is pre-compressed and the resulting 
tablets or slugs are milled to yield granules. The other method is to pre-compress the powder 
with pressure rolls using a machine such as chilsonator. 
 
Advantages: 
 
            The main advantages of dry granulation or slugging are that it uses less equipment’s 
and space. It eliminates the need for binder solution, heavy mixing equipment and the costly 
and time consuming drying step required for wet granulation. Slugging can be used for 
advantages in the following situations: 
 
 For moisture sensitive material 
 For heat sensitive material 
 For improved disintegration since powder particles are not bonded together by a   
binder. 
 
Disadvantages: 
 
 It requires a specialized heavy duty tablet press to form slug. 
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 It does not permit uniform color distribution as can be achieved with wet 
granulation where the dye can be incorporated into binder liquid. 
 The process tends to create more dust than wet granulation, increasing the 
potential contamination. 
 
Steps in dry granulation: 
 
1. Milling of drugs and excipients 
 
2. Mixing of milled powders Compression into large, hard tablets to make slug 
3. Screening of slugs 
            4. Mixing with lubricant and disintegrating agent 
5. Tablet compression two main dry granulation processes: 
 
a. Slugging process 
 
            Granulation by slugging is the process of compressing dry powder of tablet 
formulation with tablet press having die cavity large enough in diameter to fill quickly. The 
accuracy or condition of slug is not too important. Only sufficient pressure to compact the 
powder into uniform slugs should be used. Once slugs are produced they are reduced to 
appropriate granule size for final compression by screening and milling. 
 
b. Roller compaction 
 
            The compaction of powder by means of pressure roll can also be accomplished by a 
machine called chilsonator. Unlike tablet machine, the chilsonator turns out a compacted 
mass in a steady continuous flow. The powder is fed down between the rollers from the 
hopper which contains a spiral auger to feed the powder into the compaction zone. Like 
slugs, the aggregates are screened or milled for production into granule. 
 
1.7.5. By solid dispersions (35,36): 
  
            Dispersion of one or more active ingredients in an inert carrier or matrix in solid state, 
and insoluble or bland matrices may be used to mask the taste of bitter taste. Carriers used in 
solid dispersion systems include povidone, polyethelene glycols, hydroxypropyl methyl 
cellulose, urea, mannitol and ethyl cellulose.  
 
            When formulating such solid amorphous dispersions into immediate release solid 
dosage forms for oral administration to a use environment such as the GI tract of an animal 
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such as a human, it is often desirable to maximize the amount of dispersion present in the 
dosage form. This minimizes the size of the solid dosage form required to achieve the desired 
dose. Depending on the drug dose, it is often desired that the solid amorphous dispersion 
comprise at least 30 wt %, preferably at least wt %, and more preferably at least 50 wt % or 
more of the solid dosage form. Such high drug loadings of dispersion in a solid dosage form 
minimize the dosage form's size, making it easier for the patient to swallow it and tending to 
improve patient compliance.  
 
            The immediate release dosage forms containing a solid dispersion that enhances the 
solubility of a “low-solubility drug,” meaning that the drug may be either “substantially 
water-insoluble,” which means that the drug has a minimum aqueous solubility at 
physiologically relevant pH (e.g., pH 1-8) of less than 0.01 mg/mL, “sparingly water-
soluble,” that is, has an aqueous solubility up to about 1 to 2 mg/mL, or even low to moderate 
aqueous-solubility, having an aqueous-solubility from about 1 mg/mL to as high as about 20 
to 40 mg/mL.  
 
            The drug dispersions used in fabricating the high loading immediate release dosage 
forms of the present invention comprise solid dispersions of a drug and at least one 
concentration-enhancing polymer. The concentration-enhancing polymer is present in the 
dispersions used in the present invention in a sufficient amount so as to improve the 
concentration of the drug in a use environment relative to a control composition. At a 
minimum, the dispersions used in the present invention provide concentration enhancement 
relative to a control consisting of crystalline drug alone. Thus, the concentration-enhancing 
polymer is present in a sufficient amount so that when the dispersion is administered to a use 
environment, the dispersion provides improved drug concentration relative to a control 
consisting of an equivalent amount of crystalline drug, but with no concentration-enhancing 
polymer present. Various approaches for preparation of solid dispersion are described below: 
 
A. Melting Method 
 
            In this method, the drug or drug mixture and a carrier are melted together by heating. 
The melted mixture is cooled and solidified rapidly in an ice bath with vigorous stirring. This 
final solid mass is crushed and pulverized. 
 
B. Solvent Method 
 
            In this method, the active drug and carrier are dissolved in a common solvent, 
followed by solvent evaporation and recovery of solid dispersion. 
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C. Melting-Solvent Method 
 
            In this method the drug, in solution form, is incorporated into a molten mass of 
polyethylene glycol at a temperature below 700c without removing the solvent. 
 
1.6. Emesis37 
 
            Vomiting can also be referred to as emesis, and consists of the following stages: 
 
Nausea 
 
            Nausea is an unpleasant sensation of wanting to vomit, and is often associated with 
cold sweat, pallor, salivation, loss of gastric tone, duodenal contraction, and the reflux of 
intestinal contents into the stomach. Nausea generally precedes vomiting, but can occur by 
itself. The system that brings about the loss of gastric tone, of gastric relaxation, is the 
efferent part of the long loop intestinal reflex that relaxes the gut during food intake. 
 
Retching 
 
            Retching is a strong involuntary effort to vomit, and usually follows nausea. During 
retching, the abdominal muscles, chest wall and diaphragm all contract without any expulsion 
of gastric contents. 
 
Vomiting 
 
            Vomiting is the forceful expulsion of the contents of the gastrointestinal system out 
through the mouth. From an evolutionary perspective, it is thought to have evolved as a 
defense mechanism of the body, serving a protective function to rid the body of noxious 
substances that have been ingested, rather than allowing them to be retained and absorbed by 
the intestine. 
 
            Contrary to popular belief, the stomach itself does not actively expel its contents 
during vomiting. The stomach, oesophagus, and their relevant sphincters are all in fact 
relaxed during vomiting. Most of the force that expels the contents arises from the 
contraction of the diaphragm, which is the major respiratory muscle, and the abdominal 
muscles, which are the muscles involved in active expiration. 
 
1.7. Mechanisms of emesis 
 
The mechanisms of emesis can be divided into three components: 
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            Afferent inputs go to the central nervous system (CNS), relaying the signals of emetic 
stimuli; these signals are received, recognized, and centrally processed. They then form 
integrated emetic efferent signals coming from the CNS; these motor and chemical efferent 
pathways relay signals that lead to the coordinated respiratory, gastrointestinal and abdominal 
muscle expulsive actions of vomiting. 
 
 
Figure No.1.1: Mechanism of Action of Emesis 
 
Central nervous system control 
 
            There are two medullary centers of vomiting in the brain known as the sensory 
“chemoreceptor trigger zone (CTZ)” and the integrative centre. 
 
i. Chemoreceptor trigger zone (CTZ) 
 
            The CTZ is located in the medulla of the brain. It has a defensive blood-brain barrier 
for detecting circulating toxins in the blood and cerebrospinal fluid (CSF), and is sensitive to 
a number of circulating emetic agents, including morphine, intravenous copper sulphate, and 
certain circulating metabolic emetic agents associated with uremia, infections and radiation. 
When activated, the CTZ does not initiate vomiting itself, but relays stimuli to the integrative 
vomiting centre which produces the actual act of emesis. 
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ii. Integrative vomiting centre 
 
            The integrative vomiting centre coordinates activities of the nearby neural structures 
to produce a complex patterned response, resulting in the processing and action of the 
vomiting reflex. The centre is located in the medulla. The motor component of the vomiting 
centre is controlled by both somatic and autonomic systems, meaning that both voluntary and 
involuntary systems are involved in the process. Their inputs are coordinated by the vomiting 
centre. 
 
            Somatic efferent pathways control respiratory and abdominal musculature, and 
visceral efferent components mediating changes in gastric tone and motility, while salivation, 
pallor and sweating are autonomic epiphenomena. The autonomic nervous system is not 
essential for the mechanical act of vomiting, but the activation of efferent nerves of the 
abdominal organs in the emetic process is proportional to the duration and intensity of the 
nausea that accompanies the process. 
  
Afferent pathways38 
 
            The vomiting centre is predominantly activated by three different mechanisms: 
 
 By nervous impulses from the stomach, intestinal tract, and other portions of the 
body, resulting in a reflexive activation; 
 By stimulation from the higher brain centres; 
 By the chemoreceptor trigger zone (CTZ) sending impulses. 
           
Afferent impulses may also arise from other sites, such as unpleasant sights and 
odours, as well as severe parietal pain. The most common afferent pathways are in the 
viscera, or abdominal organs. Vomiting can be provoked by occlusion of the coronary vessels, 
distension of the intestine, and irritation of the gastrointestinal mucosa. In the gastrointestinal 
tract, mechanoreceptors in the intestinal wall are activated by abnormal contractions, 
distension or physical damage. Potentially harmful chemical stimuli can also activate 
chemoreceptors located in the intestinal wall. These receptors then release information to the 
vomiting centre. 
 
Efferent pathways 
 
            The neural pathways involved in the motor act of vomiting are associated mainly with 
the phrenic nerve to the diaphragm, the spinal nerves to the abdominal and intercostal 
muscles, efferent visceral autonomic fibres to the gut, and the viscera efferent fibres to parts 
of the voluntary muscles of the pharynx and larynx. The vomiting reflex is mediated by both 
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the autonomic and somatic systems, and consists of two phases: 
 
Prodomal phase (pre-ejection): Relaxation of gastric muscles followed by small 
intestinal            retrograde peristalsis; 
Ejection phase: Comprises of retching and vomiting including expulsion of gastric contents. 
 
Stimuli for vomiting: Pain, sight, smell, taste, emotion 
 
            The experience of these sensations leads to information sent to the higher centres in 
the brain, and then information relayed to the vomiting centre and CTZ via chemicals that 
transmit information to the brain, hence the name ‘neurotransmitters‘. The one that is most 
commonly responsible is acetylcholine, or Ach. Neurotransmitters stimulate and activate the 
vomiting reflex through the afferent pathways previously described. 
 
1.8. Motion sickness39 
 
            Motion sickness is due to labyrinth stimulation. The labyrinth is a part of the inner ear 
involved in balance and perception of movement. Labyrinth stimulation leads to impulses 
passing along the vestibular nerve to the central nervous system, where it activates the CTZ 
to produce emesis. Neurotransmitters such as histamine or Ach are also released to the CTZ, 
which itself can releases chemicals such as dopamine and serotonin (5HT) that go on to 
stimulate the vomiting centre, which releases Ach, which then leads to the feelings of nausea 
and actions of vomiting. 
 
1.9. Opioid medications 
 
            Opioids such as codeine, morphine, pethidine, fentanyl, methadone, oxycodon, and 
tramadol can cause nausea and vomiting through a number of  different  possible mechanisms 
such as stimulation of CTZ, increased vestibular sensitivity, gastric stasis, or impaired 
intestinal motility and constipation. 
 
1.10. Radiotherapy40 
 
            Whether radiation therapy causes nausea and vomiting depends on the part of the 
body being treated, the amount of radiation given, and how often the treatment is given. 
  
            When the area of the body being treated includes a large part of the abdomen, 
specifically, the small intestine (or small bowel), there is a greater chance of nausea and 
vomiting occurring. About 50% of the people with cancer who receive standard doses (180 to 
200 centiGray) of radiation to their abdomen will have nausea and vomiting. These 
symptoms can occur 1 to 2 hours after treatment and can last for several hours. 
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            Of those being treated with total body radiation therapy, used in bone marrow 
transplants, about 60% to 90% will develop nausea and vomiting if not given medicines to 
prevent nausea and vomiting. These people may also receive high doses of chemotherapy to 
prepare for the transplant. 
 
            The combination of radiation therapy and chemotherapy increases the chance of 
nausea and vomiting. People who receive one large dose of radiation therapy have a greater 
chance of nausea and vomiting than those who receive radiation therapy in smaller doses. 
 
1.11. Hormonal changes during pregnancy 
  
            Symptoms of nausea and vomiting are common during the first trimester of the stages 
of pregnancy. The exact mechanisms of pregnancy-induced nausea and vomiting still is not 
clear, however it is thought that elevated level of pregnancy hormones can play a role in 
inducing nausea and vomiting. Adequate hydration should be advised. Dietary modification 
such as small, frequent, high-carbohydrate, low-fat meals may help. 
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2. DRUG PROFILE 
 
METOCLOPRAMIDE HYDROCHLORIDE 
 
Table No.2.1: Metoclopramide Drug Profile 
 
Classification 
 
 
Prokinetic Agent 
 
 
Chemical Name 
 
4-Amino-5-chloro-N-[2-(diethylamino)ethyl]-o-anisamide mono- 
hydrochloride Monohydrate;4-amino-5-chloro-N-[2-
(diethylamino)-ethyl]-2-methoxybenzamidem 
monohydrochloride monohydrate. 
 
 
Structural Formula 
 
        
        
 
Empirical Formula 
 
 
C14 H22 Cl N3 O2 . HCl .H2O 
 
Category 
 
 
Antiemetic drug. 
 
Molecular Weight 
 
 
354.27 
 
Melting Point 
 
 
182-1850c 
 
Description 
 
A white or almost white, crystalline powder; odorless or almost 
odorless. 
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Identification test 
 
Shake a quantity of the powdered tablets containing 50 mg of 
anhydrous metoclopramide hydrochloride with 5ml of water. 
Filter and add to the filtrate 5ml of a 1% w/v solution of 4-
methylaminobenzaldehyde in 1 M hydrochloride acid, a yellow 
color is produced. 
 
 
Solubility  
 
 
Very soluble in water, Freely soluble in alcohol, sparingly 
soluble in chloroform, practically insoluble in ether. 
 
 
pKa 
 
 
9.71 (Teritiary aliphatic amine), 0.42(Primary aromatic amine) 
 
 
Pre-systemic 
metabolism 
 
 
32-98% 
 
pH range 
 
 
4.6-6.5 of 10% solution 
 
Plasma protein 
binding 
 
 
2.6-5.4hr 
 
Oral absorption 
 
 
Metoclopramide is rapidly and well absorbed. Relative to an 
intravenous dose of 20 mg, the absolute oral bioavailability of 
metoclopramide is 80% ± 15.5% 19. 
 
 
Dose 
 
 
10 mg (Children 0.25-0.5/kg) TDS oral or i.m. 
 
Volume of distribution 
 
 
2.2-3.4 L/kg 
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Plasma half life mean 
 
 
2.6-5.4hr 
 
Storage 
 
Metoclopramide hydrochloride should be kept in a well-
closed container, protected from light. 
 
 
 
 
 
 
Indications 
 
 Diabetic Gastroparesis (Diabetic Gastric Stasis). 
 The Prevention of Nausea and Vomiting Associated with 
Emetogenic Cancer Chemotherapy. 
 The Prevention of Postoperative Nausea and Vomiting  
      Associated with Small Bowel Intubation and in cancer  
      Therapy . 
 Radiological Examination. 
 In dyspepsia. 
 In treatment of migraine. 
 
 
 
 
 
 
 
 
 
 
Mechanism of action 
 
 
 
 Dopamine antagonists: metoclopramide which block 
the effects of dopamine in the central nervous system 
and at the chemoreceptor zone. Because of this last 
action they are effective anti-emetics. They stimulate 
peristalsis by releasing acetylcholine since their actions 
are antagonized by atropine, a muscarinic blocker. 
 
 5HT4 agonist: It acts in the GIT to enhance 
acetylcholine release for myenteric neurons. This result 
from 5HT4 receptor activation on inter neuron which 
promote acetylcholine release from the primary motor 
neurons innervating the smooth muscles. 
 
 5HT3 antagonism: At high concentrations of 
metoclopramide can block 5HT3 receptor present on 
inhibitory myentericinterneurones and in NTS/CTZ. The 
pheripheral action can augment acetylcholine release in 
gut, but appears to be minor. The central action appears 
to be minor. 
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Pharmacology 
 
 Metoclopramide stimulates motility of the upper 
gastrointestinal tract without stimulating gastric, biliary, 
or pancreatic secretions. Its mode of action is unclear. It 
seems to sensitize tissues to the action of acetylcholine. 
it can be abolished by anticholinergic drugs45. 
 Metoclopramide increases the tone and amplitude of 
gastric contractions, relaxes the pyloric sphincter and 
the duodenal bulb, and increases peristalsis of the 
duodenum and jejunum resulting in accelerated gastric 
emptying and intestinal transit. It increases the resting 
tone of the lower esophageal sphincter. It has little, if 
any, effect on the motility of the colon or gallbladder. 
 In patients with gastroesophageal reflux and low LESP 
(lower esophageal sphincter pressure), single oral doses 
of metoclopramide produce dose-related increases in 
LESP 46. 
 The onset of pharmacological action of metoclopramide 
is 1 to 3 minutes following an intravenous dose, 10 to 15 
minutes following intramuscular administration, and 30 
to 60 minutes following an oral dose; pharmacological 
effects persist for 1 to 2 hours47. 
 
 
 
 
 
 
 
 
 
Contraindications 
 
 
 Metoclopramide should not be used whenever 
stimulation of gastrointestinal motility might be 
dangerous, e.g., in the   presence of gastrointestinal 
hemorrhage, mechanical obstruction, or perforation. 
 Metoclopramide is contraindicated in patients with 
pheochromocytoma because the drug may cause a 
hypertensive crisis, probably due to release of 
catecholamines from the tumor. Such hypertensive 
crises may be controlled by phentolamine. 
 Metoclopramide is contraindicated in patients with 
known sensitivity or intolerance to the drug. 
 Metoclopramide should not be used in epileptics or 
patients receiving other drugs which are likely to cause 
extrapyramidal reactions, since the frequency and 
severity of seizures or extrapyramidal reactions may be 
increased. 
 
 
                                                                                DRUG PROFILE 
 
Department of Pharmaceutics Page Ϯϳ 
 
 
 
 
 
 
 
 
 
 
 
Pharmacokinetic 
                 
         Metoclopramide undergo variable first pass 
metabolism following oral administration    resulting in 
considerable inter individual variation in peak plasma 
concentration. Gastro-intestinal absorption may also be 
affected by conditions such as vomiting and migraine. 
Attempts to overcome these factors and achieve more 
predictable plasma concentration have been investigated 
using other route of administration23,24,25. 
 
         In a single dose study of 12 subjects, the area under 
the drug concentration-time curve increased linearly with 
doses from 20 to 100 mg. Peak concentrations increase 
linearly with dose; time to peak concentrations remains the 
same; whole body clearance is unchanged; and the 
elimination Clinical Pharmacokinetics of 
Metoclopramide21. 
 
         Renal impairment affects the clearance of 
metoclopramide. The reduction in clearance as a result of 
renal impairment suggests that adjustment downward of 
maintenance dosage should be done to avoid drug 
accumulation22. 
  
 
 
Distribution 
 
Apparent volume of distribution Metoclopramide 
Hydrochloride is 2.2-3.4 litres/ kg in adults. The drug 
crosses the blood brain barrier and placenta. It is weakly 
bound to plasma protein. 
  
 
 
 
 
Elimination 
 
 
 
 
Elimination half life (t1/2) is 4-6 hours. The t1/2  is prolonged 
in patient with renal failure. It is excreted in urine, about 
85%  of a dose being eliminated in 72 hours, 20-30% as 
unchanged. Metoclopramide and the remainder as sulfate or 
glucuronide conjugate. About 5% of  a dose is excreted  in 
faeces via the bile20. 
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Adverse Effect 
 
 
 
 
 
 Metoclopramide is a dopamine antagonist and may 
cause extrapyramidal symptoms which are usually occur 
as acute dystonic reactions especially in young female 
patient. Parkinsonism and tarditive dyskinesia have 
occasionally occurred, usually during prolonged 
treatment in elderly patient. 
 Other adverse effect includes restlessness, drowsiness, 
dizziness, head ache and bowel upsets such as 
diarrhoea. Hypotension and hyper tension and 
depression may occur and there are isolated reports of 
blood group, hypersensitivity reaction malignant 
syndrome and urinary incontinence. 
 
 
 
 
 
 
 
 
 
 
 
AdŵiŶistratioŶ for CaŶĐer 
ĐheŵotherapǇ 
 
 Early studies showed that high doses of metoclopramide 
could control nausea and  vomiting associated with the 
administration of highly emetic cytotoxic agents, 
cisplatin26. The dose of metoclopramide was 2mg per kg 
body weight by intravenous over 15 minutes, or 1mg 
per kg for 6 doses in  patient receiving lower doses of 
cisplatin. The anti-emetic protection has been reported 
to maintain with subsequent courses to upto 8 
consecutive cycles of chemotherapy28, 29. 
 High dose of oral administration of metoclopramide 
2mg per kg given 1 hour before and 1,3,5,8, and 11 
hours after initiation of cisplatin chemotherapy has been 
also found to be of benefit34, 35. 
 Metoclopramide is not effective in all patient and 
various anti-emetic regimens have been investigated 
which combine drugs with different mechanism of 
action to increase antiemetic protection36. 
Dexamethasone and lorazepam has been reported to 
enhance the antiemetic effect of metoclopramide. . 
However, the addition of diazepam to a standard 
regimen of metoclopramide maybe associated with 
increased vomiting38. 
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Administration in renal 
failure 
 
         Total clearance of metoclopramide is significantly 
reduced in patients with renal failure and the elimination 
half-life is prolonged to up to 19 hours. This may be due to 
impaired metabolism or to an alteration in enterohepatic 
circulation of metoclopramide in renal failure.  Cumulation 
of metoclopramide could therefore occur in renal failure 
with a possible increased risk of side effects .Dosage 
reduction of at least 50% have therefore been recommended 
in patients with moderate to severe renal impairement49.  
 
 
 
 
Administration for 
Amenorrhea 
 
         Metoclopramide 5 mg four times daily for 10days 
followed by 2.5mg three times daily for 20 days, and then 
this whole sequence is repeated twice , Produced menstrual 
bleeding in 7 of 8 women with amenorrhoea associated with 
normoprolactinaemia. Regular menstruation was restored in 
patient50. 
 
 
 
 
Administration for 
Aspiration syndrome 
 
 
        Metoclopramide has been investigated for the 
prevention of aspiration pneumonitis since it can increase 
lower oesophageal sphincter tone, increase gastric emptying 
and reduce emesis. A dose of 10 mg by mouth or 
intramuscularly has been reported to promote gastric 
emptying , thus reducing gastric fluid volume , during 
labour and prior to laproscopy51. 
 
 
Log p 
 
 
2.667 
 
 
 
Therapeutic Uses 
 
 
 AŶtieŵetiĐ. 
 GastrokiŶetiĐ 
 Gastroparesis 
 HiĐĐup. 
 OrthostatiĐ hǇpoteŶsioŶ 
 Gastroesophageal refluǆ disease;GERDͿ 
 Diaďetis Gastroparesis 
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Allergic Reactions 
 
 
 
A few cases of rash, urticaria, or bronchospasm, especially 
in patients with a history of asthma. Rarely, angioneurotic 
edema, including glossal or laryngeal edema. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Over Dose 
 
 Symptoms of over dosage may include drowsiness, 
disorientation and extrapyramidal reactions. 
Anticholinergic or antiparkinson drugs or 
antihistamines with anticholinergic properties may be 
helpful in controlling the extrapyramidal reactions. 
Symptoms are self-limiting and usually disappear 
within 24 hours. 
 Hemodialysis removes relatively little metoclopramide, 
probably because of the small amount of the drug in 
blood relative to tissues. Similarly, continuous 
ambulatory peritoneal dialysis does not remove 
significant amounts of drug. It is unlikely that dosage 
would need to be adjusted to compensate for losses 
through dialysis. Dialysis is not likely to be an 
effective method of drug removal in overdose 
situations. 
 Methemoglobinemia has occurred in premature and full-
term neonates who were given overdoses of 
metoclopramide (1-4 mg/kg/day orally, intramuscularly 
or intravenously for 1-3 or more days). 
Methemoglobinemia can be reversed by the intravenous 
administration of methylene blue. However, methylene 
blue may cause hemolytic anemia in patients with G6PD 
deficiency, which may be fatal. 
 
 
 
Marketed Product 
 
 
 
 
Reglan 10mg, 20mg, Perinorm 10mg, Vominorm 10mg, 
Actinorm 10mg,  
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3. EXCIPIENT PROFILE 
3.1. STARCH 
 
Synonyms:   Starch 1500, Starch I.M 
 
Nonproprietary Names:  Amylum, Polysacharide 
 
Chemical Structure:  
 
               
 
Molecular weight: 162.14g/mol 
 
Empirical formula:  (C6H12O5) 
 
Chemical Name: (2R,3S,4S,5R,6R)-2-(hydroxyl methyl)-6-[(2R,3S,4R,5R,6S)-4,5,6-
trihydroxy-2-( hydroxyl methyl)oxan-3-yl]oxy-oxane-3,4,5-triol. 
  
Physical Description 
            White colour, Odorless, Tasteless 
 
Functional Category 
            Thickening agent, stiffening agent, gluing agent, Disintegerant. 
 
Identification Test 
            Boil with 15 times its weight of water and cool; a translucent viscous fluid or jelly is 
produced which is coloured deep blue by solution of iodine; the colour disappears on 
warming and reappears on cooling.  
 
Incompatibilities 
            Incompatible with strong acids and alkali. Avoid mixing with strong oxidizing agents. 
 
Application   
            Binder,Disintegrant,   Flow aid lubricant. 
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3.2. LACTOSE 
 
Synonyms 
            Fast flow, Lactochem, Tablettose, Zeparox, granulac, Microfine, Pharmatose. 
 
Non- Proprietary Name: 
 Lactose monohydricum, Lactose monohydrate. 
 
Chemical Structure:  
 
                                   
Molecular weight : 360.31 
 
Empirical Formula: C12H22O11.H2O 
 
Chemical name :  
O- β-D-galactopyranosil-(1-4)-α-D-glycopyranose monohydrate 
 
Physical Description 
            It is a white to off-white crystalline powder. It is odourless and slightly sweet tasting. 
Functional Category: 
            Diluents for dry powder, inhaler, tablets and capsule. 
 
Identification Test 
            On heating it melts, swells up and burns, giving off an odour of burnt sugar and leaves 
bulky carbonaceous residue.    
 
Incompatibilities 
            Lactose is incompatible with aminoacids, aminophylline, ametamines, and lisinopril. 
 
Applications 
            Lactose is widely used as filler or diluent in tablets, capsules. It also used as carrier 
for inhalation and lyophilized products. 
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3.3. PROPYL PARABEN 
 
Synonym: 
 Propyl butex, Propyl chemosept, Propyl 4-hydroxybenzoate. 
 
Non- proprietary names: 
            Propyis parahydroxy benzoates, Propyl 4-hydroxy benzoates, Propyl (parahydroxy 
benzoates) 
 
Chemical structure 
 
          
 
Molecular weight:  180.2 
 
Empirical formula: C10H12O2 
  
Chemical Name: Hydroxy benzoic acid propyl ester. 
 
Physical Description 
            White crystalline powder, colourless crystals or white powder or chunky white solid 
odourless or faint aromatic odour, low toxicity and tastes.  
 
Functional Category 
            Preservatives, Food additive. 
 
Identification Test 
            Boil 10mg with 10 ml of water cool and add 0.05 ml of ferric chloride solution, a 
reddish white colour is produced.  
 
Incompatible 
            Incompatible with alkalis and metal salts. 
 
Applications 
            An antimicrobial preservative in packed foods, pharmaceuticals, cosmetics. 
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3.4. METHYL PARABEN 
 
Synonym 
            Methyl 4-OH benzoate, Nipaginm. 
 
Nonproprietary names: 
            Sodium methyl parahydroxy benzoates, Methyl paraben sodium salt. 
 
Chemical structure 
       
 
Molecular weight:  152.149g/mol 
       
Empirical formula: C10H12O2 
 
Chemical Name: 
 Methyl p- hydroxyl benzoate 
 
Physical Description 
            Soluble in water at 250c, slightly soluble in benzene, CCl4, ethanol,  Ether, acetone, 
DMSO, methanol. 
 
Functional Category:  Preservatives 
 
Identification Test 
            Boil 10mg with 10 ml of water cool and add 0.05 ml of ferric chloride solution, a 
reddish white colour is produced  
 
Incompatible 
            Incompatible with alkalis and metal salts. 
 
Applications 
            It is an antifungal agent, often used  in variety of cosmetics and personnel care 
products. It is used as food preservatives 
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3.5. TALC 
 
Synonyms 
            Altac ; E553b; hydrous magnesium calcium silicate; Purified French chalk. 
 
Nonproprietary Names: Purified Talc, JP: Talc, PhEur :Talc ,USP :Talc. 
 
Chemical Structure: 
 
 
Molecular weight: 379.259 g/mol 
 
Empirical Formula: Mg3Si4O10(OH)2 
 
Chemical Name   :  Talc. 
 
Physical Description 
            Talc is a very fine, white to greyish-white, odorless, impalpable, unctuous, crystalline 
powder. It adheres readily to the skin and is soft to touch and free from grittiness. 
 
Functional Category 
            Anticaking agents; glidant ; tablet and capsule diluent; tablet and capsules lubricant. 
 
Identification test: 
 In a lead or platinum crucible and using a copper wire, mix the sample with about 10 
mg of sodium fluoride and a few drops of sulphuric acid to give a thin slurry. Cover the 
crucible with a thin transparent plate of plastic under which a drop of water is suspended, and 
warm gently. It will give a white ring is rapidly formed around a drop of water. 
 
Incompatible 
            Mostly compatible with all other tabulating ingredients. 
 
Applications 
            Talc was widely used in oral solid dosage formulations as lubricant and diluent. Talc 
is additionally used to clarify liquids and is also used in cosmetics and food products, mainly 
for its lubricant properties.  
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3.6. SODIUM STARCH GLYCOLATE 
 
Synonyms 
            Sodium salt of  carboxy methyl ester of starch. 
 
Nonproprietary names 
            Explotab, Vivastar 
 
Chemical Structure: 
 
  
 
 
Molecular weight:  500000- 11000000 
 
Empirical formula: C2H5ONa 
 
Chemical Name: 
 Sodium salt of a cross-linked partly O-carboxymethylated potato starch. 
 
Physical Description 
            Weight to off white, Tasteless, Odorless, Relatively free flowing powder. 
 
Functional Category: Super Disintegerant, Dissolution aid, Suspending agent. 
 
Identification Test 
            Heat 5 gm. with shaking, with 40 ml of dilute sulphuric acid and cool. Filter off the 
fatty acid liberated, the filtrate gives the reaction of magnesium. 
 
Incompatible 
            Mostly compatible with all other tabulating ingredients. 
 
Applications 
            It is an antifungal agent, often used  in variety of cosmetics and personnel care 
products. It is used as food preservatives. It is also used as super disintegerant. 
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3.7. MAGNESIUM STEARATE 
 
Synonyms 
            Dibasic magnesium stearate, magnesium distearate, magnesia stearas. 
 
Nonproprietary names 
            BP: Magnesium Stearate, JP: Magnesium Stearate, PhEur : Magnesium Stearate. 
 
Chemical Structure 
            Molecular weight:  591.24    
   
Empirical Formula: Mg (C18H35O2)2 
 
Chemical Name: Octadecanoic acid magnesium salt 
 
Physical Description 
            Magnesium stearate is a very fine, light white, precipitated oromilled, impalpable 
powder of low bulk density, having a faintodorof stearic acid and a characteristic The powder 
is easy to touch and readily adheres to skin. 
 
Functional Category:  Tablet and capsule lubricant. 
 
Identification Test 
 To 5.0 add 50 ml of peroxide-free ether, 20ml of dilute nitric acid and 20ml of water 
and heat under a reflux condenser until dissolution is complete. Cool and separate the 
aqueous layer in a separating funnel and shake with ether in 2 quantities, each of 4ml, of 
water. Combine the aqueous layer, wash with 15ml of peroxide free ether and dilute to 50ml 
with water. Evaporate the organic layer to dryness and dry the residue at 1050C. this residue 
has a freezing point not less than 530C. 
 
Incompatibilities 
 Incompatible with strong acids, alkalis and iron salts. Avoid mixing with strong 
oxidizing materials. 
 
Applications 
            Magnesium stearate is widely used in cosmetics food and pharmaceuticals 
formulations. It is primarily used as a lubricant in capsule and tablet manufacture at 
concentration between 0.25% and 5.0% w/w. It is also used in barrier cream. 
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3.8. INNOVATOR CHARACTERISTICS 
 
Brand Name Perinorm 
Content Name Metoclopramide 
Dose 10mg 
Route of Administration Oral 
Dosage Immediate release tablet dosage form 
Packing Description Blister Packing, 10 tablets in one strip. 
Storage Condition Store in a cool and dry place 
Manufacturer IPCA Laboratories 
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4. LITERATURE REVIEW 
 
1. EL Parrot3.: This article deals with the study of the energetic relationships during 
compaction and the properties of tablets produced from a co-processed excipient based on 
starch. ®. The study also includes the mixtures of StarCap 1500® and the granulated 
directly compressible lactose. The tablet properties tested included tensile strength and 
disintegration time, examined in dependence on compression force, and also a 0.4% 
addition of magnesium stearate. The results show a better compressibility of StarCap 
1500 in comparison with Starch 1500 and a lower elastic component of energy. The 
tablets were stronger and disintegrated more rapidly, but the substance possessed a higher 
sensitivity to an addition of a lubricant than Starch 1500. Increasing portions of StarCap 
1500 in the mixtures with Pharmatose DCL 15 increased the tensile strength of tablets, 
disintegration period as well as the sensitivity to an addition of a lubricant. From the 
energetic viewpoint, energy for friction was decreasing, while the energy accumulated by 
the tablet during compaction and the elastic component of energy were increased3. 
 
2. Rudolph M navari et.al20: The localization of substance P in brain stem regions 
associated with vomiting, and the result of studies in ferrets, led us to postulate that a 
neurokinins-1-receptor antagaonist would be an antiemetic in patient receiving anticancer 
chemotherapy. The neurokinin-1—receptor antagonist with gransetron plus 
dexamethasone improves the prevention of acute emesis. 
 
3. Paul J Hesketh el.at25:  New sight into the pathophysiology of chemotheraphy-induced 
nausea and vomiting, a better understanding of patient at risk, and the availability of new 
antiemetic agents have all contributed to substantial improvement in emetic control. This 
review focuses on our current understanding of chemotherapy induced nausea and 
vomiting and the status of pharmacologic interventions in its prevention and treatment. 
 
4. Monica R P Rao
31
: The development of immediate release tablet formulations is based 
on the use of super disintegrants separately or in combination. Seven formulations were 
prepared using simplex centroid mixture design where sodium starch glycolate, cross 
carmellose sodium and pre-gelatinised starch were selected as independent variables and 
dependent variables. Response surface plots were drawn, and optimum formulations were 
selected by grid search method. Formulations when used individually gave satisfactory 
results but when used in combination gave better results. The results showed a good 
relationship between the experimental and predicted values, which confirms the 
predictability of the model. 
5. Bhandari Neeraj el. At
51
:  The basic approach used in this study is that development 
tablets is the use of superdisintegrants which provide instantaneous disintegration of 
tablet after administration. The development of immediate release tablets also provides an 
opportunity for a line extension in the market place. As a drug entity nears the end of its 
patent life, it is common for pharmaceutical manufacturers to develop a given drug entity 
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in a new and improved dosage form.  Now a day, immediate release formulations are 
similar to many sustained release formulations that are now commonly available..  
 
6. Nyol Sandeep
36
: Immediate drug release dosage forms disintegrate rapidly after 
administration with enhanced rate of dissolution. The basic approach used in development 
of tablets is the use of superdisintegrants like Sodium starch glycolate (Primogel, 
Explotab).  These superdisintegrants provide  instantaneous  disintegration of tablet after 
administration in stomach. In this field immediate release liquid dosage forms and 
parenteral dosage form have also been introduced for treating patients. In liquid dosage 
form can be suspensions with typical dispersion agents like hydroxypropyl 
methylcellulose, AOT etc. The development of immediate release therapy also provides 
an opportunity for a line extension in the marketplace, a wide range of drugs e.g., 
neuroleptics, cardiovascular drugs, analgesics, antihistamines and other drugs can be 
considered candidates for this dosage form. As a drug entity nears the end of its patent 
life, it is common for pharmaceutical manufacturers to develop a given drug entity in a 
new and improved dosage form. A new dosage form allows a manufacturer to extend 
market exclusivity, while offering its patient population a more convenient dosage form 
or dosing regimen. 
 
7. Molassiotis, A. et al.
38
: He evaluated acute chemotherapy-induced nausea and vomiting 
(CINV) prophylaxis; provided sufficient information to permit determination of the 
emetogenicity of the antineoplastic therapy administered or the study investigators stated 
the emetogenicity of the chemotherapy administered; included an implicit or explicit 
definition of complete acute CINV response; described the antiemetic regimen in full; and 
reported the complete acute CINV response rate as a proportion. The findings of several 
randomized trials were used to update recommendations for the prevention of acute 
CINV. 
 
8. Ripamonti. C.et al.
39
: The aim of this paper is to review the existing literature related to 
the management of nausea and vomiting (N & V) in advanced cancer and derive clinical 
evidence-based recommendations for its management. These new guidelines, based on 
the existing (but poor) evidence, could help clinicians manage more effectively the 
complex and challenging symptoms of N & V in advanced cancer. 
 
9. H.C. Stewart et.el.40:  The causes of nausea, vomiting and retching and how these are 
brought about are explained, and the present views on the mechanism of vomiting are 
discussed. The sites of action of sensory stimuli causing vomiting are linked in a figure 
with the probable sites of action of anti-emetic drugs. Three main groups of anti-emetic 
drugs are discussed, general sedatives and tranquillizers, oscine and atropine, and certain 
antihistamines. The results of some clinical trials are considered and suggestions made for 
the best combination of drugs. Undesirable side effects, particularly those of the 
phenothiazines, are stressed so that suitable precautions can be taken in their use. 
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10. Gupta et al.
52
: The principal aim of this work was to find out the effect of sodium starch 
glycol ate and β – cyclodextrin on the dissolution profile of immediate release telmisartan 
tablets and to optimize their values by a 2
2
full factorial design. Other excipients used in 
the study are microcrystalline cellulose (Avicel PH-101) and magnesium stearate. Both 
sodium starch glycolate and β – cyclodextrin had contribution towards the immediate 
release but the effect of sodium starch glycolate is more pronounced from response 
surface plot as well as from the contour plot. The optimised amount of sodium starch 
glycolate and β – cyclodextrin were found to be 55.714 mg and 30 mg respectively for 70 
% drug release at 30 minutes.  
 
11. V. M. Thakare et al.53: In this work, orodispersible tablets of Metoclopramide HCl were 
prepared by direct compression techniques using complex of drug with various 
superdisintegrant. Before formulation of tablets, the best superdisintegrant among Tulsion 
339, Ac-Di-Sol, and Sodium starch glycolate was formulated with drug and tested. For 
taste masking ion exchange resin Tulsion 339 Drug: Tulsion339, 1:2.25 ratios was used. 
The blends were examined for precompression parameters. The result were complies with 
Pharmacopeial and non-official limits. The prepared batches of tablets were evaluated for 
post compression parameters. Formulations were tested for in vitro drug release pattern 
(in pH 6.8 buffer), Batch F5 containing Tulsion 339 showed better disintegrating 
character along with the immediate release . 
 
12. Margret C R et.al.54: It was studied Effect of formulated ingredients on rapidly 
disintegerating oral tablets prepared by the crystalline transition method.  
 
13. Yunxia B et.al
57
: Tablets were prepared by direct compression technique. The granules 
were evaluated for angle of repose, bulk density, tapped density, bulkiness, 
compressibility index and hausners ratio. The tablets were evaluated for hardness, 
thickness, uniformity of weight, friability, wetting time, water absorption ratio, 
disintegeration time and drug content. In vitro release studies were performed using USP-
II (paddle method) in 900ml of pH 1.2 at 50 rpm. The physical properties of the prepared 
tablets did not show any significant varitions and were found to have good physical 
integrity. Tablets prepared with pharmaburst B2 and carmellose sodium showed a lesser 
disintegerationtime and wetting time of 27±0.10 and 38±0.13 seconds respectively. 
 
14. Prakash khadka et. al.65: in this study showed that Pharmaceutical particle technology is 
employed to improve poor aqueous solubility of drug    compounds that limits in vivo 
bioavailability owing to their low dissolution rate in the    gastrointestinal fluids following 
oral administration. The particle technology involves several approaches from the 
conventional size reduction processes to the newer, novel particle technologies that 
modify the solubility properties of the drugs and produce solid, powdered form of the 
drugs that are readily soluble in water and can be easily formulated into various dosage 
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forms. This review highlights the solid particle technologies available for improving 
solubility, dissolution and bioavailability of drugs with poor aqueous solubility. 
 
15. Samran et al.
66
: The objective of the study was to characterise STE as excipient and to 
use STE as excipient in the formulation of ODT by lyophilisation method. The 
ingredients were glutinous rice used to form tapai and the liquid extract of tapai which 
was used to make STE. STE was used as excipient by combining STE with dextrose and 
avicel. Metoclopramide HCl was used as a drug model. The design of formula used the 
simplex lattice design (SLD) model with a three components mixture: STE, dextrose and 
avicel as excipients. The parameters of lyophilised ODT (LODT) were hardness and 
friability, wetting time, disintegrating time and dissolution rate. The results showed STE 
can be used as filler and binder for LODT. STE could also function as disintegrant and 
formed porosity in the lyophilised method.  
 
16. vander Meer .et .al .67: Regulatory agencies in North America and Europe recently re-
evaluated the safety of metoclopramide. This re-evaluation resulted in recommendations 
and restrictions in order to minimize the risk of neurological and other adverse reactions 
associated with the use of metoclopramide. In the ICU, off-label prescription of 
metoclopramide is common. We have reviewed the evidence for safety, effectiveness and 
dosing of metoclopramide in critically ill patients. Furthermore, tachyphylaxis is 
addressed and alternatives are summarized. Finally, recommendations are presented not to 
abandon use of metoclopramide in ICU patients, because metoclopramide is considered 
effective in enhancing gastric emptying and facilitating early enteral nutrition. 
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5. AIM AND OBJECTIVE 
 
5.1 Aim of the Study: 
 
            The main aim of the present study is to develop a pharmaceutically equivalent, low 
cost, quality improved formulation of immediate release dosage form of Metoclopramide 
Hydrochloride 10 mg for the treatment of emesis. Evaluation and optimization of process 
parameters as well as finished dosage form also form part of this work comparable to 
innovator product. 
 
 The term “immediate release” pharmaceutical formulation includes any formulation 
in which the rate of release of drug from the formulation or the absorption of drug, is neither 
appreciably, nor intentionally, retarded by galenic manipulations. These tablets which 
disintegrate rapidly and get dissolved to release the medicaments. It may be provided for by 
way of an appropriate pharmaceutically acceptable diluent or carrier, which diluent or carrier 
does not prolong, to an appreciable extent, the rate of drug release or absorption. 
 
5.2 Objective 
 
The main objective of this study was: 
 
A. To formulate and evaluate immediate release of Metoclopramide 
hydrochloride tablets. 
 
B. To study the release profile of the dosage form and to compare their drug 
release profiles with the innovator. 
 
C. To determine the best fit dissolution profile for dosage form. 
 
D.  To study the stability of dosage form. 
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6. PLAN OF WORK 
 
            The present work was carried out to formulate and evaluate the immediate release 
tablet of Metoclopramide tablets. 
 
  
A. Preformulation Studies: 
    
 Description 
 
 Melting Point 
 
 Thin layer Chromatography 
 
 pH Range 
 
 Drug Excipient Compatibility Studies (FTIR) 
 
 
B. Method of Drug Analysis 
 
C. Evaluation Parameters 
 
 Bulk Density 
 
 Tapped Density 
 
 Angle of Repose 
 
 Carr’s Index 
 
 HausŶer Ratio 
 
 Sieve AŶalǇsis 
 
 PhǇsiĐal StaďilitǇ of Adŵiǆture. 
 
 
D. Formulation of Metoclopramide Hydrochloride Immediate release Tablets. 
 
 
E. Preparation of Metoclopramide Hydrochloride Tablets. 
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F. Post Compression Parameters 
         
 Thickness 
  
 Hardness 
 
 Weight Variation 
    
 Friability 
          
 Wetting time 
 
 Drug Content Uniformity 
          
G. In vitro disintegeration time 
 
H. In vitro dissolution study 
 
I. Stability studies of the optimized formulation 
 
J. Comparison of Formulated and Marketed Tablets. 
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7. MATERIALS AND METHODOLOGY 
 
Table No. 7.1: List of Materials 
 
S. No 
 
 
Materials 
 
Use 
 
Sources 
 
1 
 
Metoclopramide 
Hydrochloride 
 
Active Ingredient 
 
Valkunth Chemicals Pvt 
.Ltd 
 
2 
 
Starch 
 
Disintegerant  
and Binder 
 
Universal Starch Chem 
Allied 
Limited. 
 
3 
 
Lactose 
 
Diluent 
 
Saputo Ingredients Inc. 
 
4 
 
Methyl paraben 
 
Preservatives 
 
 
Nebula Healthcare 
 
5 
 
Propyl paraben 
 
Preservatives 
 
Nebula HealthCare 
 
6 
 
Talc 
 
Lubricant 
 
Neelkanth Minechem 
 
7 
 
Magnesium Stearate 
 
Glidant 
 
Legend Industries 
 
8 
 
Sodium starch glycolate 
 
Super 
disintegerant 
 
 
Maple Biotech Pvt.Ltd 
 
 
Chemicals 
 
1 
 
Hydrochloric acid 
 
Mercks Laboratories Pvt.Ltd  
 
2 
 
Sodium hydroxide 
 
Mercks Laboratories Pvt.Ltd 
 
3 
 
Sodium sulphate 
 
Mercks Laboratories Pvt.Ltd 
 
4 
 
Potassium hydroxide 
 
Mercks Laboratories Pvt.Ltd 
 
5 
 
Potassium dihydrogen phosphate 
 
Mercks Laboratories Pvt.Ltd 
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Equipments 
Table No.7.2: List of Equipment 
 
S. No 
 
Instrument Used 
 
Manufacturer 
 
1 
 
Electronic weighing balance 
 
 
Mettler, Switzerland 
 
2 
 
Max mixer 
 
Innofab India pvt.ltd, 
Hyderabad 
 
3 
 
Fluidized bed dryer 
 
Alliance, Bombay 
 
4 
 
Cadmill 
 
Cadmach, Ahemedabad 
 
5 
 
Tablet Compression Machine 45 station 
double rotary 
 
Cadmach, Ahemedabad 
 
6 
 
Friability Tester 
 
Veego, Mumbai 
 
7 
 
Tablet Hardness Tester 
 
Electrolab, Mumbai 
 
8 
 
Bulk density apparatus 
 
Electrolab, Mumbai 
 
 
9 
 
Blender 
 
Bhuvaneswari, Mumbai 
 
10 
 
Dissolution Apparatus 
 
Veego, Mumbai 
 
11 
 
Tablet Disintegeration Apparatus 
 
Veego, Mumbai 
 
12 
 
FT-IR Spectrophotometer 
 
 
Perkin Elmer, USA 
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 METHODOLOGY 
 
7.1. Preformulation Studies44 
 
            Preformulation study relates to pharmaceutical and analytical investigation carried out 
proceeding and supporting formulation development efforts of the dosage form of the drug 
substance. Preformulation yields basic knowledge necessary to develop suitable formulation 
for the toxicological use. It gives information needed to define the nature of the drug 
substance and provide frame work for the drug combination with pharmaceutical recipients in 
the dosage form. Hence, the following Preformulation studies were performed on the 
obtained sample of drug. 
          
Objective45 
 
            The overall objective of preformulation testing is to generate information useful in 
developing the formulation which is stable and bioavailable. Further the use of 
preformulation parameters maximizes the chances in formulating an acceptable, safe, 
efficacious and stable product. For any drug substance to formulate into a dosage form, it is 
necessary to study the physicochemical properties of the bulk drug like description, 
solubility, identification test, melting point, molecular weight. 
 
Description: 
        
            The drug sample was analysed for physical appearance, color, and odour. 
 
Melting point48 
 
            Determination of Melting Point: Melting point of drug was determined by capillary 
method. Fine powder of drug was filled in a glass capillary tube (previously sealed at one 
end). The capillary tube is tied to thermometer and the thermometer was placed in the Thieles 
tube and this tube is placed on fire. The powder at what temperature it will melt was noticed. 
 
Thin Layer Chromatography: 
 
Standard Preparation: Dissolve USP Metoclopramide Hydrochloride in Methanol 
and mix to obtain a solution having a known concentration of 1mg per mL 
 
Test Preparation: Dissolve an accurately quantity of Metoclopramide Hydrochloride 
in methanol to obtain a solution containing 50 mg per mL. Dilute a portion of this preparation 
quantitatively with methanol to obtain a solution containing 500 µgm per ml. Apply 10µL in 
a chromatographic plate coated with silica gel mixture. Allow the spot to dry and Position the 
plate in a chromatographic chamber containing the solvent system consisting of a mixture of 
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chloroform, methanol, toluene and ammonium hydroxide until the solvent front has moved 
about the three fourth of the chromatographic plate. Then examine the plate under UV light 
and compare the intensity. Test preparation is more intense than standard preparation and 
sum of all intensities of all secondary preparation is not more than 1%. 
   
pH Range : 
 
            pH of a 0.10 g/mL solution in carbon-dioxide-free water R, 4.5-6.5. 
 
FTIR analysis63: 
 
            The FTIR spectra of the pure drug were recorded in between 4000 to 400 cm-1.  The 
drug sample and the excipients were characterized using FTIR analysis. FTIR spectra for, 
lactose, starch shown in figure. 
 
7.2. Method of Drug Analysis62: 
 
Preparation of standard stock solution: 
 
            Standard drug solution of Metoclopramide Hydrochloride was prepared by dissolving 
10 mg metoclopramide hydrochloride in deionized water, phosphate buffer pH 6.8 and 
simultated Gastric Fluid (pH1.2) separately and the volume was made upto 100ml to obtain 
stock solution of 100 μg/ml concentration. Ultrasonication was done to obtain a clear 
solution. 
 
UV Spectroscopic scan: 
 
1. A stock solution of Metoclopramide hydrochloride tablet of concentration 100 μg/ml 
prepared in deionised water. The UV spectrum was recorded in  the range of 200-
400nm. The wavelength of maximum absorption was found to be 273.0nm. 
2. A stock solution of Metoclopramide hydrochloride tablet of concentration 100 μg/ml 
prepared in phosphate buffer pH 6.8. The UV spectrum was recorded in the range of 
200-400nm. The wavelength of maximum absorption was found to be 273.80nm.  
3. A stock solution of Metoclopramide hydrochloride tablet of concentration 100 μg/ml 
prepared in 0.1 N HCL. The UV spectrum was recorded in the range of 200-400nm. 
The wavelength of maximum absorption was found to be 273.50nm. 
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Construction of calibration curve: 
 
            Aliquots of 0.5 to 3.5 ml portion of stock solution was transferred to a series of 10 ml 
volumetric flask, and volume made upto the mark with deionised water, Phosphate buffer pH 
6.8 and simultated gastric pH 1.2 and prepared solution of 5,10,15,20,25,30 and 35 μg/ml. 
The solution was analysed using UV Spectrometer and calibration curve was plotted. The 
result shown in 
 
7.3 Evaluation Parameters 
 
Determination of bulk density and tapped density46 
 
            It refers to a measurement to describe packing of particles and also used to determine 
the amount of drug that occupies the volume in mg/ml before tapping and after tapping. 
 
            An accurately weighed quantity of the powder (W), was carefully poured into the 
graduated cylinder and the volume (Vo) was measured, then the graduated cylinder was 
closed with lid, set into the density determination apparatus. The density apparatus was set 
for 500 taps and after that, the volume (Vf) was measured and continued operation till the two 
consecutive readings were equal. 
 
            The bulk density and tapped density were calculated using the following formula: 
 
 
 
 
 
 
                                                            
 
                                                             
                                                 Where, 
 
                                                            W = weight of the powder 
                                                             Vo = initial volume 
                                                             Vf = final volume 
 
 
 
 
 
 
 
Bulk density = W / Vo 
Tapped density = W / Vf 
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Flow Properties49 
 
            The flow properties are measured by angle of repose. Improper flow of powder is due 
to frictional forces between the particles. These frictional forces are quantified by angle of 
repose. 
 
            Angle of repose is defined as the maximum angle possible between the surface of a 
pile of the powder and the horizontal plane. 
 
            Angle of repose was determined by using fixed funnel method. The fixed funnel 
method employ a funnel that was secured with its tip at a given height (2cm), above the graph 
paper that was placed on a flat horizontal surface. Granules or tablet blend were carefully 
poured through the funnel until the apex of the conical pile just touches the tip of the funnel. 
Thus, with r being the radius of the base of the conical pile. 
 
                                    
 
 
                                                     
 
                                           Where, 
 
 h=height of pile. 
r= radius of the base of pile. 
 θ =angle of repose. 
 
Table No. 7.3: Relationship belongings angle of repose and powder flow 
 
 
S. NO 
 
 
Angle of repose (θ) 
 
Flow 
 
1 
 
<25 
 
Excellent 
 
2 
 
25-30 
 
Good 
 
3 
 
30-40 
 
Passable 
 
4 
 
 
40 & Above 
 
Very Good 
 
  tanθ = h/r                        θ = tan-1 h/r 
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Compressibility Index 
 
Compressibility was calculated from the powder density using the following formula: 
 
 
 
                                
 
                                                                                        
    
                                            Where, 
 
                                                        TD – Tapped density 
                                                        BD – Bulk density 
 
 
Table No. 7.4: Compressibility Index range 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.No 
 
Percentage 
Compressibility Index 
 
 
Flow ability 
 
1 5-15 
 
Excellent 
2 12-16 
 
Good 
3 18-21 
 
Passable 
4 23-35 
 
Poor 
5 33-38 
 
Very poor 
6 <40 
 
Very Very poor 
CI = (TD−BD) TD x100  
TD 
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Hausner Ratio: 
 
            It indicates the flow property of the powder and measured by the ratio of tapped 
density to bulk density. 
 
Table No. 7.5: Hausner Ratio Properties 
 
 
 
 
 
 
  
 
 
Sieve analysis 
 
            The main aim of sieve analysis is to determine the different size of drug particles 
present. A series of standard sieve were stacked one above the other so that sieves with larger 
pore size (less sieve number) occupy top position followed by sieves with smaller pore size 
(greater sieve number towards the bottom). 
 
Table No. 7.6: Relationship belongings Nature of sample and different particle size. 
 
 
S. No 
 
 
Nature of Sample 
 
Result of Determination 
 
1. 
 
Coarse powder 
 
 
NLT 95% of the sample mass pass through 14# and 
NMT 40% pass through 36# 
2. Moderately coarse 
Powder 
NLT 95% of the sample mass pass through 25# and 
NMT 40% pass through 60# 
3. Moderately fine 
powder 
NLT 95% of the sample mass pass through 36# and 
NMT 40% pass through 40# 
4. Fine powder NLT 95% of the sample mass pass through 100# and 
NMT 40% pass through 150# 
5. Very fine powder NLT 95% of the sample mass pass through 150# and 
NMT 40% pass through 200# 
6. Super fine powder NLT 95% by number of particles less than 10 
 
 
Hausner Ratio 
  
Properties 
 
0-1.2 
 
Free flowing 
 
1.2-1.6 
 
Cohesive powder 
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7.4. Formulation of Metoclopramide Hydrochloride Tablets 
 
 Metoclopramide Hydrochloride Tablets Immediate Release tablets were prepared by wet granulation method. 
 
Table No. 7.7: Formulation of Metoclopramide Hydrochloride Tablets
 
S. No 
 
Ingredients 
(in mg) 
 
Formulations 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 Metoclopramide 
Hydrochloride 
10 10 10 10 10 10 10 10 10 
2 Starch 54.2 59.2 64.2 54.2 59.2 64.2 54.2 52.2 64.2 
3 Lactose 29.5 24.5 19.5 30 4.5 19 29 24 19 
4 Methyl paraben    sodium 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 0.18 
5 Propyl paraben sodium 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 0.12 
6 Starch for paste 4 4 4 4 4 4 4 4 4 
7 Talc 1 1 1    1 1 1 
8 Magnesium stearate 1 1 1  1 1 1 1 1 1 
9 Sodium starch glycolate    0.5 1 1.5 0.5 1 1.5 
10 Total weight (in mg) 100 100 100 100 100 100 100 100 100 
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7.5. Preparation of Metoclopramide Hydrochloride Tablets 
 
1. Sieving 
 
            The active ingredients and the other excipients are passed through sieve no     #22.  
After sieving, they are collected to suitable baskets. 
 
2. Dry Mixing  
 
            Above sieved materials are collected and then add into MCG.  Dry mixing is achieved 
by low speed for 15 min. 
 
3. Wet granulation 
 
i.  Preparation of Binder solution 
       
           Take the calculated amount of Starch in a S.S vessel and dissolved 
it in specified amount of water and then boils at 1000C. Then this solution 
is added to another solution containing required amount of Methyl Paraben 
and Propyl Paraben which is heated at 600C. Stir it well. 
 
ii.  Mixing  
      
            Add binder solution to the above sieved material which mixing for 
5-15 min in MCG in slow speed. Change the mixer speed to fast and mix 
for 5- 15 min till the end point achieved. Then pass through the cad mill to 
achieve required type of granules. Then scrap the materials from the cad 
mill. 
 
4. Drying 
 
            Load the powder in the fluidized bed dryer. Dry the moist granules. Check the loss on 
drying at more than 0.5%.  
 
5. Pulverization 
 
        Pass the dried granules through the cad mill with Super disintegerant, lubricants and 
glidants. Then collect the required type of granules by passing through the 14#150 mesh and 
get uniform sized granules. 
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6. Lubrication  
 
       All the above ingredients are collected and lubricated by using double cone blender. 
 
7. Compression 
 
i. Then the lubricated dry blends were subjected to punching using a tablet 
punching machine with Punch size: 6mm round punches 
 
ii. Tablet weight : 100mg 
 
iii. Hardness: 3.6 - 3.8Kg/cm2 
 
iv. Thickness: 2.7mm 
 
v. Friability: NMT 0.80%w/w 
 
            Parameters like average weight, hardness and friability were checked during 
compression as in process quality measures. 
 
7.6. Post Compression Parameters 
 
A. Thickness and diameter50: 
 
            Control of physical dimension of the tablet such as thickness and diameter is essential 
for consumer acceptance and tablet uniformity. The thickness and diameter of the tablet was 
measured using Vernier calipers. It is measured in mm. A ± 5% may be allowed depending 
on the size of the tablet. 
 
B. Hardness test51: 
 
            One tablet was placed vertically between the anvil and the punch of Strong Cobb 
Hardness tester. The tablet was clamped by turning the regulator screw until the signal "stop" 
lighted, and then the button was pressed until the tablet broke. After the tablet broke, the 
scale number was recorded. The tablet hardness was the figure of the needle on the scale. 
Hardness test was performed for 6 tablets. 
 
C. Weight variation test52: 
 
            The weight of the tablet being made in routinely measured to ensure that a tablet 
contains the proper amount of drug. The USP weight variation test was done by weighing 20 
tablets individually, calculating the average weight and comparing the individual weights to 
the average. The tablet meet the USP test if not more than 2 tablets are outside the percentage 
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limits and if no tablets differs by more than 2 times the percentage limit. USP official limits 
of percentage deviation of tablet are presented in the following table, 
 
Table No.7.8:  Weight variation limits53: 
 
 
 
 
 
                                               Where,  
                                                        PD = Percentage deviation, 
                                                        W avg= Average weight of tablet, 
                                                        W initial =individual weight of tablet. 
 
D. Friability test54: 
 
            Friability is the loss of weight of tablet in the container due to removal of fine 
particles from the surface. Friability test is carried out to access the ability of the tablet to 
withstand abrasion in packaging, handling and transport. Roche friabilator was employed for 
finding the friability of the tablets. 20 tablets from each formulation were weighed and placed 
in Roche friabilator that rotated at 25 rpm for 4 minutes. The tablets were deducted and 
weighed again. The percentage of weight loss was calculated again. The percentage of weight 
loss was calculated using the formula. 
 
 
% Friability =    (W1- W2)   x 100 
               W1 
                                
 
                                         Where, 
W1= Weight of tablet before test 
                                                 W2 = Weight of tablet after test 
 
Sl.No Aǀerage ǁeight of a 
taďlet ;ŵg) 
Maxiŵuŵ differeŶĐe 
alloǁed ;%Ϳ 
ϭ ϭϯϬ or less ϭϬ 
Ϯ ϭϯϬ-ϯϮϰ 7.ϱ 
ϯ ϯϮϰ or  more ϱ 
 
% Friability =    (W1- W2)   x 100 
                   W1 
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E. Wetting time 
 
            The wetting time of the tablets was measured using a simple procedure. Five circular 
tissue papers of 10cm diameter were placed in a petri dish with a 10cm diameter. Ten 
milliliters of water containing eosin, a water-soluble dye, was added to the petridish. A tablet 
was carefully placed on the surface of tissue paper. The time required for water to reach the 
upper surface of the tablets was noted as the wetting time. 
 
G. Drug content uniformity56: 
 
            Weigh and powder 20 tablets. Weigh accurately a quantity of the powder equivalent 
to 10 mg of anhydrous Metoclopramide hydrochloride, add 50 ml of 0.1M hydrochloric acid, 
heat on a water-bath at 700C for 15 minutes, cool, dilute to 100.0 ml with water and filter. To 
20.0 ml of this solution add 15 ml of 1.25M sodium hydroxide and extract with three 
quantities, each of 30 ml, of chloroform, dry each extract with anhydrous sodium sulphate 
and filter. Dilute the combined extracts to 100.0 ml with chloroform and mix. Measure the 
absorbance of the resulting solution at the maximum at about 305 nm.  
           
H. In-vitro Disintegration time57: 
 
            The in-vitro disintegration time was determined using disintegration test apparatus. 
One tablet was placed in each of the six tubes of the apparatus and one disc was added to 
each tube. The time in seconds taken for complete disintegration of the tablet with no 
palatable mass remaining in the apparatus was measured in seconds. Tablet was added to 
water at 37±0.5°c. Time required for complete disintegration of tablet was measured. 
 
I. In-vitro dissolution study58: 
 
            In vitro drug release study of Metoclopramide HCl was performed in USP dissolution 
apparatus Type 2 (paddle).Phosphate buffer pH 1.2 was used as a dissolution media. The 
bowls of the dissolution tester was filled with 900 ml of phosphate buffer PH 1.2 and allows 
to attaining a temperature of 37±0.5ºc and 50 rpm. Dissolution apparatus was started. At 
predetermined time interval. 5ml sample withdrawal and addition of fresh dissolution media. 
The collected samples were filtered and absorbance of the solution was measured at 273.5 
nm. The concentration of Metoclopramide HCl was calculated using slope of calibration 
curve and cumulative percentage release was calculated. 
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7.7. Stability study 
     
            Stability of a drug has been defined as the ability of a particular formulation, in a 
specific container, to remain within its physical, chemical, therapeutic and toxicological 
specifications. The purpose of stability testing is to provide evidence on how the quality of a 
drug substance or drug product varies with time under the influence of a variety of 
environmental factors such as temperature, humidity and light, and enables recommended 
storage conditions, retest periods and shelf lives to be established59.           
 
            FDA’s Current Good Manufacturing Practice regulations include sections on stability 
and stability testing of pharmaceutical components and finished pharmaceutical products. In 
addition, FDA and International Conference on Harmonization guidelines and guidance’s 
provide working recommendations to support the regulatory requirements. Among these are 
the following 60: 
 
        • “Stability Testing of New Drug Substances and Products” 
        • “Quality of Biotechnological Products: Stability Testing of     
             Biotechnology/Biological Drug Products”      
        • “Photo stability Testing of New Drug Substances and Products” 
        • “Stability Testing of New Dosage Form. 
            Drug and drug product stability testing during every stage of development is critical 
to the quality of the product. For a marketed drug product, assurance of stability is vital to its 
safety and effectiveness during the course of its shelf life and use61. 
 
7.8. Storage condition 
 
            In general, a drug product should be evaluated under storage condition that tests its 
stability and if applicable, its sensitivity to moisture or potential for solvent loss. The long 
term testing should cover a minimum of 12 months study or at least three batches at the time 
of submission and should be continued for a period of sufficient time till it covers the 
proposed shelf life. Stability studies were conducted at different conditions of 40ºc/ 75% RH 
and 25ºc/ 60% RH for about 3months in stability chamber (thermo lab). Samples were 
collected at 1st month, 2nd month and 3rd month. 
 
7.9. Comparison Study 
 
            The precompression parameters and the postcompression parameters of drug are 
compared between the optimized tablet and marketed tablet  
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8. RESULTS AND DISCUSSION 
 
8.1. Preformulation Studies of Metoclopramide Hydrochloride 
 
a. Organoleptic character 
 
            All the organoleptic character of paroxetine Hydrochloride was studied and it was 
found that all the character complies with USP standards. 
 
Table No. 8.1: Characterization of Drug 
 
 
 
 
 
 
 
 
 
 
 
 
 
1. The FTIR Spectrum of Metoclopramide Hydrochloride 
 
The FTIR absorption of Metoclopramide Hydrochloride (Pure drug) were recorded in 
between 4000 to 400 cm-1. Characteristics peak  and chemical  group  present  in  IR  
spectrum  of Metoclopramide  was  showed  in . 
 
 
 
 
Test 
 
 
Specification 
 
Result 
Colour White Confirms 
Odour Odourless Confirms 
Physical State Crystalline Powder Confirms 
Melting point 1820C-1850C 1830C 
Thin Layer 
Chromatography 
Test Preparation is more 
intense than Standard 
Preparation 
Confirms 
pH of Water Solution 4.5- 6.5 Confirms 
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Figure No. 8.1: FTIR spectra of metoclopramide hydrochloride 
 
 
 
Table No .8.2: Spectral assignment of metoclopramide hydrochloride 
 
 
 
 
 
 
 
 
 
 
 
 
S. No 
 
 
Functional Group 
 
Frequency 
(cm-1) 
 
 
1 
 
C=O 
1600 
 
2 
 
O-H, N-H 
3200, 3300,3340, 
3400,3460. 
 
3 
 
NH (Amide) 
 
1540 
 
4 
 
C-O 
 
1270 
 
5 
 
C-Cl 
 
700 
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Figure No. 8.2: FTIR spectra of Metoclopramide Hydrochloride and Starch 
   
 
Figure No. 8.3: FTIR spectra of metoclopramide hydrochloride and Lactose 
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The FTIR of drug and Starch shown intense band at 3413 cm-1, 1418 cm-1, 1024, 422 
cm-1 indicates no change in the functional groups NH, C=Cl and C=O, C-O. The FTIR of 
Drug and Lactose showed intense band at 3417 cm-1, 1500 cm-1, 1082, 528 cm-1. From the 
above interpretation it is understood that there is no major shifting in the frequencies of above 
said functional groups. Hence these drug and excipients are compatible with each other. 
 
b. Method of Drug Analysis 
 
Construction of   Calibration Curve in Deionised Water 
 
As shown in the figure, the calibration curve of Metoclopramide Hydrochloride 
follows linear relationship and the curve obeyed Beer-Lambert law within concentration 
range of 5-35 ugm/ml. The correlation coefficient value (R2) was found to be 0.9987. 
 
Table No. 8.3: Calibration curve in Deionized Water 
 
 
 
 
 
 
 
 
 
 
 
Figure No: 8.4: Calibration curve of Metoclopramide Hydrochloride in Deionised water. 
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SL. No 
 
Concentration (µgm/ml) 
 
Absorbance (nm) 
1 5 0.286 
2 10 0.561 
3 15 0.826 
4 20 1.061 
5 25 1.312 
6 30 1.621 
7 35 1.934 
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In Phosphate Buffer pH 6.8 
 
As shown in the figure, the calibration curve of Metoclopramide Hydrochloride 
follows linear relationship and the curve obeyed Beer-Lambert law within concentration 
range of 5-35 ugm/ml. The correlation coefficient value (R2) was found to be 0.9987. 
 
Table No. 8.4:  Calibration Curve in Phosphate Buffer pH 6.8 
Sl. No Concentration (µgm/ml) Absorbance (nm) 
1 5 0.224 
2 10 0.442 
3 15 0.676 
4 20 0.891 
5 25 1.11 
6 30 1.402 
7 35 1.622 
 
 
 
 
Figure No. 8.5: Calibration curve in phosphate buffer 
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In Stimulated Gastric pH (0.1N HCl) 
 
As shown in the figure, the calibration curve of Metoclopramide Hydrochloride 
follows linear relationship and the curve obeyed Beer-Lambert law within concentration 
range of 5-35 (µgm/ml). The correlation coefficient value (R2) was found to be 0.9989.  
 
Table No. 8.5: Calibration curve in simulated Gastric Fluid 
 
SL. No 
 
Concentration (µgm/ml) 
 
Absorbance (nm) 
 
1 
 
5 
 
0.160 
 
2 
 
10 
 
0.312 
 
3 
 
15 
 
0.456 
 
4 
 
20 
 
0.616 
 
5 
 
25 
 
0.746 
 
6 
 
30 
 
0.938 
 
7 
 
35 
 
0.972 
 
 
 
 
 
Figure No. 8.6: Calibration curve in simulated Gastric Fluid 
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8.2. Evaluation Parameters: 
 
a. Pre-compression parameters 
 
The Metoclopramide hydrochloride granules was prepared and subjected to pre-
compression parameters like bulk density, Tapped density, carr’s index, sieve analysis and 
angle of repose. All the pre-compression parameters was evaluated and reported in table no: 
8.6. 
 
Bulk Density and Tapped Density 
 
The bulk density of all the powder blend batch of Metoclopramide  hydrochloride  
was found to be 0.59g/cm3 to 0.66g/cm3and the tapped density of the entire powder blend 
batch was found to be 0.71g/cm3 to 0.80g/cm3showing good flow property. 
 
Angle of Repose 
 
The angle of repose of the drug and excipients was evaluated. The angle of repose of 
the entire powder blend of each formulation was found in between 25-290 which reveals the 
blend has a good flow property. Hence it is confirmed that all blends has free flow property. 
 
Carr’s Index 
 
The measurement of free flowing powder can also be done by Carr’s index. The 
Carr’s index for all the formulations was found to be 12-14.6 which reveals that the blends 
have fair flow character. 
 
Hausner Ratio 
 
The Hausner ratio of drug and Excipients was done as per procedure. The hausner 
ratio of the entire powder blend of each formulation was found in between 1.14-1.2 which 
reveals that the blend is free flowing. So it is confirmed that all the blend has free flow 
property.  
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Table No. 8.6: Results of Pre-compression parameters 
 
 
Parameters 
 
Bulk 
Density 
(g/cm3) 
 
 
Tapped 
density 
(g/cm3) 
 
Carr’s 
Index (%) 
 
 
Angle of 
Repose 
(θ) 
 
Hausner 
Ratio 
F1 0.59 0.75 12 25.25 1.2 
F2 0.63 0.73 13.69 26.27 1.15 
F3 0.61 0.71 14.08 27.32 1.16 
F4 0.60 0.70 13.79 26.65 1.16 
F5 0.62 0.71 12.67 28.42 1.14 
F6 0.64 0.74 13.51 29.96 1.15 
F7 0.63 0.72 12.5 25.07 1.14 
F8 0.66 0.76 13.15 26.56 1.15 
F9 0.64 0.75 14.66 27.60 1.17 
 
 
Sieve Analysis 
 
The sieve analysis was determined by Mechanical sieve shaker. Since 80% drug 
particles were retained in sieve no 50, and about 18.5% of drug particles were retained on 
sieve no 18. Hence the particles lay between sieves no 50 and 18. The drug has a particle size 
lies between 297μm to 1mm.  
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Table No.8.7: Particle size determination of Metoclopramide hydrochloride 
 
Sieve 
No 
 
Microns 
 
Wt of 
drug + 
sieve (g) 
Wt of the 
drug 
retained 
(g) 
% of 
drug 
retained 
 
Cumulative 
% of drug 
(μ) retained 
#18 1000 389.7 3.7 18.5 18.5 
#50 297 360 16 80 98.5 
#70 210 331.3 0.3 1.5 100 
#120 125 340 0 0 0 
#140 105 338 0 0 0 
#170 88 325 0 0 0 
#200 74 320 0 0 0 
#200 
Pass 
 460 0 0 0 
 
 
  20 100  
 
 
Physical Stability of the Admixture 
 
The drugs along with the excipients were kept under conditions specified and the 
results are given 
 
 
Table No. 8.8: Drug – Excipient stability profile 
 
There was no physical change observed in the admixture after one month at 60 ºC 
 
 
S. No 
 
 
Items 
 
1 Month/Control 
 
 
1Month/ 600C 
1 API No change No change 
2 API+ Lactose No change No change 
3 API+ Starch No change No change 
4 API+ Talc No change No change 
5 API+ Magnesium stearate No change No change 
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8.3. Post Compression Parameters 
 
            The tablets of different formulations of Metoclopramide Hydrochloride were 
subjected to various evaluation tests, such as hardness, thickness weight variation, friability 
and drug content. All the result is shown in Table 8.9. 
 
Thickness 
 
The thickness of the tablets was found out using Vernier Caliper and the thickness 
found to be in the range of 4.02-4.12mm for the uncoated tablets (F1-F6). For the enteric 
coated tablets the thickness ranged from 4.21-4.30.Thus all formulations showed uniform 
thickness. 
 
Hardness test 
 
The hardness of tablet was measured by Monsanto hardness tester. Ten tablets from 
the batch were used for hardness studies and results showed they were in between 3.5- 4.2 
Kg/cm2. 
 
Weight variation test 
 
In a weight variation, the pharmacopoeial limit for the percentage deviation for tablets 
of more than 250 mg is ±5%. The average percentage deviation of all tablet formulations was 
found to be within the above limit, and hence all formulations passed the test for uniformity 
of weight as per official requirements. 
 
Friability test 
 
The Friability of all the formulation was below 1% as per IP specification. 
 
Wetting Time 
  
 The wetting time of tablet was measured and the result found in between 35- 45 
seconds.  
 
Drug content analysis 
  
Metoclopramide Hydrochloride tablet was tested for their drug content and all the 
formulation showed drug content 90 to 110%. 
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All the tablet formulations showed acceptable pharmaco-technical properties and 
complied with the in-house specifications for weight variation, drug content, hardness, and 
friability. 
 
Table No. 8.9: Results of post compression parameters 
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F1 
 
 
 
3.7 
 
 
0.69 
 
102.3±0.15 
 
98.94±0.25 
 
2.7 
 
 
36 
 
42±0.73 
 
F2 
 
 
3.9 
 
 
0.71 
 
 
101.2±0.66 
 
99.46±0.24 
 
2.7 
 
39 
 
51±0.58 
 
F3 
 
4.2 
 
0.68 
 
98.9±0.301 
 
99.65±0.33 
 
2.7 
 
45 
 
55±0.65 
 
F4 
 
 
3.6 
 
0.71 
 
100.6±0.23 
 
99.45±0.12 
 
2.7 
 
38 
 
34±0.59 
 
F5 
 
 
3.5 
 
 
0.74 
 
102.1±0.18 
 
99.25±0.31 
 
2.7 
 
40 
 
41±0.85 
 
F6 
 
 
4.1 
 
 
0.72 
 
101.3±0.26 
 
99.52±0.06 
 
2.8 
 
43 
 
45±0.71 
 
F7 
 
 
3.7 
 
0.69 
 
101.6±0.22 
 
99.86±0.39 
 
2.7 
 
35 
 
30±0.64 
 
F8 
 
 
3.9 
 
0.71 
 
99.5±0.18 
 
99.78±0.35 
 
2.7 
 
39 
 
32±0.48 
 
F9 
 
 
4.1 
 
 
0.70 
 
100.8±0.21 
 
99.42±0.14 
 
2.8 
 
42 
 
35±0.40 
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8.4 .Drug Release Study 
 
Innovator drug release profile 
 
Cumulative percent drug released from the tablet were shown 
 
Table No. 8.10: In-vitro Drug release profile of Innovator 
 
S. No 
 
 
Time 
 (Min) 
 
Percentage cumulative drug release 
1 3 35.50 
2 6 46.40 
3 9 79.40 
4 12 92.68 
5 15 99.58 
 
 
 
 
Figure No. 8.7: In-vitro Drug release profile of Innovator 
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Result of Drug release for F5 formulation 
 
         Cumulative percent drug released from the tablet were shown 
 
Table No. 8.11: In-vitro Drug release profile of F5 batch 
 
S. No 
 
 
Time 
(Min) 
 
Percentage cumulative drug release 
F5 Innovator 
1 3 30.24 35.50 
2 6 61.18 46.40 
3 9 89.12 79.40 
4 12 93.92 92.68 
5 15 94.42 99.58 
 
 
 
 
 
Figure No. 8.8: In-vitro Drug release profile of F5 batch 
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Result of Drug release for F6 formulation 
 
 Cumulative percent drug released from the tablet were shown 
 
Table No. 8.12: In-vitro Drug release profile of F6 batch 
 
 
S. No 
 
 
Time 
(Min) 
 
Percentage cumulative drug release 
F6 Innovator 
1 3 31.11 35.50 
2 6 73.56 46.40 
3 9 89.38 79.40 
4 12 92.18 92.68 
5 15 93.76 99.58 
 
 
 
Figure No. 8.9: In-vitro Drug release profile of F6 batch 
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Result of Drug release for F7 formulation 
  
Cumulative percent drug released from the tablet were shown 
 
Table No. 8.13: In-vitro Drug release profile of F7 batch 
 
 
S. No 
 
 
Time 
(Min) 
 
Percentage cumulative drug release 
F7 Innovator 
1 3 32.46 35.50 
2 6 76.11 46.40 
3 9 90.18 79.40 
4 12 97.34 92.68 
5 15 99.10 99.58 
 
 
 
 
  Figure No. 8.10: In-vitro Drug release profile of F7 batch 
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Result of Drug release for F8 formulation  
 
Cumulative percent drug released from the tablet were shown 
 
Table No. 8.14: In-vitro Drug release profile of F8 batch 
 
S. No 
 
 
Time 
(Min) 
 
Percentage cumulative drug release 
F8 Innovator 
1 3 32.24 35.50 
2 6 63.18 46.40 
3 9 90.12 79.40 
4 12 95.92 92.68 
5 15 96.26 99.58 
 
 
 
 
Figure No. 8.11: In-vitro Drug release profile of F8 batch 
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Result of Drug release for F9 formulation 
 
Cumulative percent drug released from the tablet were shown 
 
Table No. 8.15: In-vitro Drug release profile of F9 batch 
 
S. No 
 
 
Time 
(Min) 
 
Percentage cumulative drug release 
F9 Innovator 
1 3 32.18 35.50 
2 6 73.56 46.40 
3 9 88.56 79.40 
4 12 94.24 92.68 
5 15 95.16 99.58 
 
 
 
 
Figure No. 8.12: In-vitro Drug release profile of F9 batch 
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Drug Release of various formulation 
 
Table No. 8.16: In-vitro Drug release profile of various formulation and innovator 
 
 
 
Time 
(Min) 
 
Formulation 
 
F5 
 
F6 
 
F7 
 
F8 
 
F9 
 
Innovator 
3 
 
30.24 31.11 32.46 32.24 32.18 35.50 
6 
 
61.18 73.56 76.11 63.18 73.56 56.40 
9 
 
89.12 89.38 90.18 90.12 88.56 76.40 
12 
 
93.92 92.18 97.34 95.92 94.24 92.68 
15 94.42 93.76 99.10 96.26 95.16 99.58 
 
 
 
 
 
Figure No. 8.13: Comparison of In-vitro Drug release profile with Marketed Product 
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8.5. Stability Study 
Aging studies of formulated immediate release tablet of Metoclopramide 
Hydrochloride at 250C/ 60% RH (2 month) 
 
Table No .8.17: Stability studies of optimized formulation F7 at 250C/ 60% RH. 
 
S. No 
 
 
Evaluation 
Parameters 
 
 
Observation 
Initial 1 Month 2 Months 
 
1 
 
 
Physical Appearance 
 
White 
 
White 
 
White 
 
2 
 
Weight variation (%) 
 
 
101.6±0.22 
 
101.9±0.22 
 
101.9±0.22 
 
3 
 
Friability (%) 
 
 
0.69 
 
0.71 
 
0.71 
 
4 
 
Thickness (mm) 
 
 
2.7±0.051 
 
2.7±0.046 
 
2.7±0.056 
 
5 
 
Hardness (kg/cm2) 
 
 
3.70±0.18 
 
3.68±0.27 
 
3.68±0.29 
 
6 
 
Disintegeration Time 
(sec) 
 
30±0.64 
 
28±0.54 
 
28±0.59 
 
8 
 
Drug content (%) 
 
 
99.86±0.25 
 
99.85±0.15 
 
99.85±0.23 
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Stability Study  
 
Aging studies of formulated immediate release tablet of Metoclopramide 
Hydrochloride at 400C/ 75% RH (2 month.) 
 
 
Table No .8.18: Stability studies of optimized formulationF7 at 400C/ 75% RH. 
 
 
S. No 
 
 
Evaluation 
Parameters 
 
 
Observation 
Initial 1 Month 2 Months 
 
1 
 
 
Physical Appearance 
 
White 
 
White 
 
White 
 
2 
 
Weight variation (%) 
 
 
101.6±0.22 
 
101.8±0.35 
 
101.8±0.22 
 
3 
 
Friability (%) 
 
 
0.69 
 
0.71 
 
0.72 
 
4 
 
Thickness (mm) 
 
 
2.7±0.053 
 
2.7±0.42 
 
2.7±0.048 
 
5 
 
Hardness (kg/cm2) 
 
 
3.70±0.21 
 
3.65±0.26 
 
3.65±0.29 
 
6 
 
Disintegeration Time 
(sec) 
 
30±0.62 
 
28±0.54 
 
28±0.60 
 
8 
 
Drug content (%) 
 
 
99.86±0.28 
 
99.86±0.35 
 
99.85±0.39 
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8.6. Stability study of in-vitro dissolution for formulation F7 stored at 
different temperature 
 
Table No .8.19: Stability study of In-vitro dissolution of optimized formulation 
 
 
 
 
Time 
(Min) 
 
Cumulative% Drug Release 
 
Stored at 250C Temperature 
 
Stored at 400C Temperature 
 
After 1 Month 
 
After 2 Months 
 
After 1 Month 
 
After 2 Months 
 
3 
 
31.42 
 
31.08 
 
31.38 
 
30.96 
 
6 
 
74.85 
 
74.52 
 
74.45 
 
74.36 
 
9 
 
89.18 
 
88.98 
 
88.84 
 
88.53 
 
12 
 
96.34 
 
96.12 
 
96.38 
 
95.97 
 
15 
 
98.98 
 
98.97 
 
98.94 
 
98.91 
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8.7. Comparison of Formulated and Marketed Tablets 
 
            The Precompression parameters of drug are compared between the formulated tablet 
F7 and Marketed tablet are shown below: 
 
Table No 8.20: Comparison of Formulated and Marketed Tablets 
 
 
Sl. No 
 
Parameters 
 
F7 
 
Marketed Tablet 
 
1 
 
Average weight of Tablet(mg) 
 
101.6±0.22 
 
140±0.58 
 
2 
 
Hardness 
(kg/cm2) 
 
3.7±0.16 
 
3.9±0.21 
 
3 
 
Friability (%) 
 
0.69 
 
0.26 
 
4 
 
Wetting Time 
(%) ±S.D 
 
35±0.64 
 
32±0.58 
 
5 
 
Uniformity of Drug Content 
(%)  ± S.D 
 
99.86±0.32 
 
99.80±0.28 
 
6 
 
Disintegration Time (sec) 
± S.D 
 
30±0.62 
 
25±0.53 
 
7 
 
Thickness(mm) 
 
 
2.7±0.043 
 
2.2±0.064 
 
8 
 
 
Drug Release (%) 
 
99.58 
 
99.10 
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8.8. Formulation of Immediate Release tablets of Metoclopramide 
Hydrochloride  
 
 
 
 
Figure No. 8.15: Formulation of Immediate Release tablets of Metoclopramide 
Hydrochloride 
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9. SUMMARY 
               
            The present study was under taken to formulate and evaluate the immediate release 
tablets of Metoclopramide hydrochloride by using wet granulation technique with various 
disintegerants. The study involves pre-formulation ofdrug and excipients, formulation, 
evaluation and stability studies. 
 
            Nine formulations of metoclopramide were prepared by using various disintegerant in 
different concentration. The optimized formulation was selected according to the result found 
from the evaluation parameter of each formulation. Estimation of drug was carried out 
spectrometrically by UV method. Pre-formulation study involving FTIR showed no 
interaction between drug and excipients. 
  
            The selected drug Metoclopramide was taken and formulated with different 
concentration of starch, talc and sodium starch glycolate. The tablets were prepared by wet 
granulation method and then it is punched after subjecting the blend to pre-compression 
parameters like Angle of repose (25.070), Bulk density (0.63gm/cm), Tapped 
density(0.72g/cm3), Carr’s Index (12.5%), Hausner ratio (1.14). The results obtained were 
satisfactory. The Post compression parameters like Hardness (3.7kg/cm2), Weight variation 
(101.6%), Friability (0.69%), Drug content analysis (99.86%), Disintegeration time (30sec) 
and In-vitro dissolution studies (99.10 at 15 min) were also carried out and tabulated. Among 
all these formulations F7 was selected as optimized formulation. 
  
            The selected optimized formulation was characterized with stability studies. These 
tablets were subjected to pre-compression parameters and post-compression parameters. 
These results were compared with the predetermined optimized formulation results. The 
formulation was found to be stable. 
 
            The prepared in-vitro dissolution studies of prepared immediate release tablet were 
compared with that of marketed formulations and were found to be better than them.  
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10. CONCLUSION 
 
            The Present study was conducted to formulate and evaluate the immediate release 
tablet of Metoclopramide hydrochloride. Pre-formulation study was carried out initially with 
study of selection of superdisintegrants was done and different formulations were prepared 
using sodium starch glycolate and starch as disintegerants. Immediate release tablet of 
Metoclopramide hydrochloride was prepared by wet granulation method. The tablet 
disintegrated rapidly and has an acceptable friability and hardness. In vitro drug release from 
the tablets shows significantly improved drug dissolution. Hence it could be concluded that 
the superdisintegrant based on immediate release tablet of Metoclopramide hydrochloride 
would be quite effective in emesis, providing quick onset of action on administration. 
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